<!DOCTYPE HTML>
<html lang="en-uk">


<head>
    <meta charset="utf-8">
    <meta name="keywords" content="Immunity, Infection and Respiratory System, 天何言哉">
    <meta name="description" content="Consultation Skills
Gastrointestinal

Dyspepsia, GORD, constipation, diarrhoea, threadworm, IBS, haemorrhoids

Dyspepsia">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=no">
    <meta name="renderer" content="webkit|ie-stand|ie-comp">
    <meta name="mobile-web-app-capable" content="yes">
    <meta name="format-detection" content="telephone=no">
    <meta name="apple-mobile-web-app-capable" content="yes">
    <meta name="apple-mobile-web-app-status-bar-style" content="black-translucent">
    <meta name="referrer" content="no-referrer-when-downgrade">
    <!-- Global site tag (gtag.js) - Google Analytics -->

<script async src="https://www.googletagmanager.com/gtag/js?id=G-CFBH42KL3R"></script>
<script>
    window.dataLayer = window.dataLayer || [];
    function gtag() {
        dataLayer.push(arguments);
    }

    gtag('js', new Date());
    gtag('config', 'G-CFBH42KL3R');
</script>


    <title>Immunity, Infection and Respiratory System | 天何言哉</title>
    <link rel="icon" type="image/png" href="/favicon.png">
    


    <!-- bg-cover style     -->



<link rel="stylesheet" type="text/css" href="/libs/awesome/css/all.min.css">
<link rel="stylesheet" type="text/css" href="/libs/materialize/materialize.min.css">
<link rel="stylesheet" type="text/css" href="/libs/aos/aos.css">
<link rel="stylesheet" type="text/css" href="/libs/animate/animate.min.css">
<link rel="stylesheet" type="text/css" href="/libs/lightGallery/css/lightgallery.min.css">
<link rel="stylesheet" type="text/css" href="/css/matery.css">
<link rel="stylesheet" type="text/css" href="/css/my.css">
<link rel="stylesheet" type="text/css" href="/css/dark.css" media="none" onload="if(media!='all')media='all'">




    <link rel="stylesheet" href="/libs/tocbot/tocbot.css">
    <link rel="stylesheet" href="/css/post.css">




    



    <script src="/libs/jquery/jquery-3.6.0.min.js"></script>

<meta name="generator" content="Hexo 6.3.0">
<style>.github-emoji { position: relative; display: inline-block; width: 1.2em; min-height: 1.2em; overflow: hidden; vertical-align: top; color: transparent; }  .github-emoji > span { position: relative; z-index: 10; }  .github-emoji img, .github-emoji .fancybox { margin: 0 !important; padding: 0 !important; border: none !important; outline: none !important; text-decoration: none !important; user-select: none !important; cursor: auto !important; }  .github-emoji img { height: 1.2em !important; width: 1.2em !important; position: absolute !important; left: 50% !important; top: 50% !important; transform: translate(-50%, -50%) !important; user-select: none !important; cursor: auto !important; } .github-emoji-fallback { color: inherit; } .github-emoji-fallback img { opacity: 0 !important; }</style>
<link rel="alternate" href="/atom.xml" title="天何言哉" type="application/atom+xml">
</head>


<body>
    <header class="navbar-fixed">
    <nav id="headNav" class="bg-color nav-transparent">
        <div id="navContainer" class="nav-wrapper container">
            <div class="brand-logo">
                <a href="/" class="waves-effect waves-light">
                    
                    <img src="/medias/logo.png" class="logo-img" alt="LOGO">
                    
                    <span class="logo-span">天何言哉</span>
                </a>
            </div>
            

<a href="#" data-target="mobile-nav" class="sidenav-trigger button-collapse"><i class="fas fa-bars"></i></a>
<ul class="right nav-menu">
  
  <li class="hide-on-med-and-down nav-item">
    
    <a href="/" class="waves-effect waves-light">
      
      <i class="fas fa-home" style="zoom: 0.6;"></i>
      
      <span>Index</span>
    </a>
    
  </li>
  
  <li class="hide-on-med-and-down nav-item">
    
    <a href="/tags" class="waves-effect waves-light">
      
      <i class="fas fa-tags" style="zoom: 0.6;"></i>
      
      <span>Tags</span>
    </a>
    
  </li>
  
  <li class="hide-on-med-and-down nav-item">
    
    <a href="/categories" class="waves-effect waves-light">
      
      <i class="fas fa-bookmark" style="zoom: 0.6;"></i>
      
      <span>Categories</span>
    </a>
    
  </li>
  
  <li class="hide-on-med-and-down nav-item">
    
    <a href="/archives" class="waves-effect waves-light">
      
      <i class="fas fa-archive" style="zoom: 0.6;"></i>
      
      <span>Archives</span>
    </a>
    
  </li>
  
  <li class="hide-on-med-and-down nav-item">
    
    <a href="/about" class="waves-effect waves-light">
      
      <i class="fas fa-user-circle" style="zoom: 0.6;"></i>
      
      <span>About</span>
    </a>
    
  </li>
  
  <li class="hide-on-med-and-down nav-item">
    
    <a href="/contact" class="waves-effect waves-light">
      
      <i class="fas fa-comments" style="zoom: 0.6;"></i>
      
      <span>Contact</span>
    </a>
    
  </li>
  
  <li class="hide-on-med-and-down nav-item">
    
    <a href="/friends" class="waves-effect waves-light">
      
      <i class="fas fa-address-book" style="zoom: 0.6;"></i>
      
      <span>Friends</span>
    </a>
    
  </li>
  
  <li>
    <a href="#searchModal" class="modal-trigger waves-effect waves-light">
      <i id="searchIcon" class="fas fa-search" title="Search" style="zoom: 0.85;"></i>
    </a>
  </li>
  <li>
    <a href="javascript:;" class="waves-effect waves-light" onclick="switchNightMode()" title="深色/浅色模式" >
      <i id="sum-moon-icon" class="fas fa-sun" style="zoom: 0.85;"></i>
    </a>
  </li>
</ul>


<div id="mobile-nav" class="side-nav sidenav">

    <div class="mobile-head bg-color">
        
        <img src="/medias/logo.png" class="logo-img circle responsive-img">
        
        <div class="logo-name">天何言哉</div>
        <div class="logo-desc">
            
            鸿蒙初辟本无性，打破顽冥须悟空
            
        </div>
    </div>

    <ul class="menu-list mobile-menu-list">
        
        <li class="m-nav-item">
	  
		<a href="/" class="waves-effect waves-light">
			
			    <i class="fa-fw fas fa-home"></i>
			
			Index
		</a>
          
        </li>
        
        <li class="m-nav-item">
	  
		<a href="/tags" class="waves-effect waves-light">
			
			    <i class="fa-fw fas fa-tags"></i>
			
			Tags
		</a>
          
        </li>
        
        <li class="m-nav-item">
	  
		<a href="/categories" class="waves-effect waves-light">
			
			    <i class="fa-fw fas fa-bookmark"></i>
			
			Categories
		</a>
          
        </li>
        
        <li class="m-nav-item">
	  
		<a href="/archives" class="waves-effect waves-light">
			
			    <i class="fa-fw fas fa-archive"></i>
			
			Archives
		</a>
          
        </li>
        
        <li class="m-nav-item">
	  
		<a href="/about" class="waves-effect waves-light">
			
			    <i class="fa-fw fas fa-user-circle"></i>
			
			About
		</a>
          
        </li>
        
        <li class="m-nav-item">
	  
		<a href="/contact" class="waves-effect waves-light">
			
			    <i class="fa-fw fas fa-comments"></i>
			
			Contact
		</a>
          
        </li>
        
        <li class="m-nav-item">
	  
		<a href="/friends" class="waves-effect waves-light">
			
			    <i class="fa-fw fas fa-address-book"></i>
			
			Friends
		</a>
          
        </li>
        
        
        <li><div class="divider"></div></li>
        <li>
            <a href="https://github.com/blinkfox/hexo-theme-matery" class="waves-effect waves-light" target="_blank">
                <i class="fab fa-github-square fa-fw"></i>Fork Me
            </a>
        </li>
        
    </ul>
</div>


        </div>

        
            <style>
    .nav-transparent .github-corner {
        display: none !important;
    }

    .github-corner {
        position: absolute;
        z-index: 10;
        top: 0;
        right: 0;
        border: 0;
        transform: scale(1.1);
    }

    .github-corner svg {
        color: #0f9d58;
        fill: #fff;
        height: 64px;
        width: 64px;
    }

    .github-corner:hover .octo-arm {
        animation: a 0.56s ease-in-out;
    }

    .github-corner .octo-arm {
        animation: none;
    }

    @keyframes a {
        0%,
        to {
            transform: rotate(0);
        }
        20%,
        60% {
            transform: rotate(-25deg);
        }
        40%,
        80% {
            transform: rotate(10deg);
        }
    }
</style>

<a href="https://github.com/blinkfox/hexo-theme-matery" class="github-corner tooltipped hide-on-med-and-down" target="_blank"
   data-tooltip="Fork Me" data-position="left" data-delay="50">
    <svg viewBox="0 0 250 250" aria-hidden="true">
        <path d="M0,0 L115,115 L130,115 L142,142 L250,250 L250,0 Z"></path>
        <path d="M128.3,109.0 C113.8,99.7 119.0,89.6 119.0,89.6 C122.0,82.7 120.5,78.6 120.5,78.6 C119.2,72.0 123.4,76.3 123.4,76.3 C127.3,80.9 125.5,87.3 125.5,87.3 C122.9,97.6 130.6,101.9 134.4,103.2"
              fill="currentColor" style="transform-origin: 130px 106px;" class="octo-arm"></path>
        <path d="M115.0,115.0 C114.9,115.1 118.7,116.5 119.8,115.4 L133.7,101.6 C136.9,99.2 139.9,98.4 142.2,98.6 C133.8,88.0 127.5,74.4 143.8,58.0 C148.5,53.4 154.0,51.2 159.7,51.0 C160.3,49.4 163.2,43.6 171.4,40.1 C171.4,40.1 176.1,42.5 178.8,56.2 C183.1,58.6 187.2,61.8 190.9,65.4 C194.5,69.0 197.7,73.2 200.1,77.6 C213.8,80.2 216.3,84.9 216.3,84.9 C212.7,93.1 206.9,96.0 205.4,96.6 C205.1,102.4 203.0,107.8 198.3,112.5 C181.9,128.9 168.3,122.5 157.7,114.1 C157.9,116.9 156.7,120.9 152.7,124.9 L141.0,136.5 C139.8,137.7 141.6,141.9 141.8,141.8 Z"
              fill="currentColor" class="octo-body"></path>
    </svg>
</a>
        
    </nav>

</header>

    
<script src="/libs/cryptojs/crypto-js.min.js"></script>
<script>
    (function() {
        let pwd = '';
        if (pwd && pwd.length > 0) {
            if (pwd !== CryptoJS.SHA256(prompt('请输入访问本文章的密码')).toString(CryptoJS.enc.Hex)) {
                alert('密码错误，将返回主页！');
                location.href = '/';
            }
        }
    })();
</script>




<div class="bg-cover pd-header post-cover" style="background-image: url('/medias/featureimages/13.jpg')">
    <div class="container" style="right: 0px;left: 0px;">
        <div class="row">
            <div class="col s12 m12 l12">
                <div class="brand">
                    <h1 class="description center-align post-title">Immunity, Infection and Respiratory System</h1>
                </div>
            </div>
        </div>
    </div>
</div>




<main class="post-container content">

    
    <div class="row">
    <div id="main-content" class="col s12 m12 l9">
        <!-- 文章内容详情 -->
<div id="artDetail">
    <div class="card">
        <div class="card-content article-info">
            <div class="row tag-cate">
                <div class="col s7">
                    
                    <div class="article-tag">
                        
                            <a href="/tags/Biology/">
                                <span class="chip bg-color">Biology</span>
                            </a>
                        
                    </div>
                    
                </div>
                <div class="col s5 right-align">
                    
                    <div class="post-cate">
                        <i class="fas fa-bookmark fa-fw icon-category"></i>
                        
                            <a href="/categories/Course-Notes/" class="post-category">
                                Course Notes
                            </a>
                        
                    </div>
                    
                </div>
            </div>

            <div class="post-info">
                
                <div class="post-date info-break-policy">
                    <i class="far fa-calendar-minus fa-fw"></i>Publish Date:&nbsp;&nbsp;
                    2025-11-29
                </div>
                

                
                <div class="post-date info-break-policy">
                    <i class="far fa-calendar-check fa-fw"></i>Update Date:&nbsp;&nbsp;
                    2025-12-03
                </div>
                

                
                <div class="info-break-policy">
                    <i class="far fa-file-word fa-fw"></i>Word Count:&nbsp;&nbsp;
                    7.7k
                </div>
                

                
                <div class="info-break-policy">
                    <i class="far fa-clock fa-fw"></i>Read Times:&nbsp;&nbsp;
                    45 Min
                </div>
                

                
            </div>
        </div>
        <hr class="clearfix">

        
        <!-- 是否加载使用自带的 prismjs. -->
        <link rel="stylesheet" href="/libs/prism/prism.min.css">
        

        

        <div class="card-content article-card-content">
            <div id="articleContent">
                <h2 id="Consultation-Skills">Consultation Skills</h2>
<h3 id="Gastrointestinal">Gastrointestinal</h3>
<blockquote>
<p>Dyspepsia, GORD, constipation, diarrhoea, threadworm, IBS, haemorrhoids</p>
</blockquote>
<h4 id="Dyspepsia-and-GORD">Dyspepsia and GORD</h4>
<h5 id="Red-Flags">Red Flags</h5>
<ul>
<li>Blood in vomit or stools</li>
<li>Difficulty swallowing</li>
<li>Unexplained weight loss</li>
<li>Over 40 and first presentation</li>
<li>Pain radiating down arm/cardiac association (Dyspepsia only)</li>
</ul>
<p>Timescale for referral: 5-7 days</p>
<h5 id="Product-selection">Product selection</h5>
<ul>
<li>
<p>PPI – both conditions</p>
<ul>
<li>Reduce acid production</li>
<li>Long duration of action but also 2-3 day delay</li>
<li>Up to 14 days treatment, &gt;18</li>
<li><strong>Esomeprazole/omeprazole</strong></li>
</ul>
</li>
<li>
<p>Antacids – both conditions</p>
<ul>
<li>Liquid or chewable tablets</li>
<li>Neutralise excess acid - Effect short lived but immediate</li>
<li>Liquids can be used in children</li>
<li><strong>Bisodol/Rennie/Mag trisilicate/Maalox</strong> etc</li>
</ul>
</li>
<li>
<p>Alginates – mostly GORD</p>
<ul>
<li>Liquid or chewable tablets</li>
<li>Form a raft to protect the oesophagus and usually</li>
<li>mixed with an antacid</li>
<li>Effect short lived but immediate</li>
<li>Usually, &gt;12 years old</li>
<li><strong>Gaviscon</strong></li>
</ul>
</li>
</ul>
<h3 id="Skin-conditions">Skin conditions</h3>
<blockquote>
<p>Eczema, contact dermatitis, acne vulgaris, burns and scalds, bites and stings</p>
</blockquote>
<h3 id="Infectious-skin-conditions">Infectious skin conditions</h3>
<blockquote>
<p>Warts and verrucas, fungal skin infections, scabies, impetigo, herpes simplex/shingles</p>
</blockquote>
<h3 id="Respiratory">Respiratory</h3>
<blockquote>
<p>cough, cold, hay fever</p>
</blockquote>
<h4 id="Cough">Cough</h4>
<h5 id="Red-Flags-2">Red Flags</h5>
<ul>
<li>Chest pain</li>
<li>Pain on inspiration</li>
<li>Wheezing 喘息</li>
<li>Shortness of breath</li>
<li>Coughing up blood</li>
</ul>
<p>Check for sputum – differential diagnosis 检查痰液</p>
<p>Timescale for referral: More than 3 weeks duration see GP</p>
<h5 id="Product-selection-2">Product selection</h5>
<ul>
<li>
<p>Chesty/productive cough - Expectorants 有痰咳嗽 - 祛痰药</p>
<ul>
<li>Guaifenesin (Benylin chesty cough, Robitussin chesty cough) 愈创甘油醚</li>
</ul>
</li>
<li>
<p>Demulcents 润喉</p>
<ul>
<li>Simple linctus</li>
</ul>
</li>
<li>
<p>Dry/non productive cough</p>
<ul>
<li>Pholcodine (Galenphol, Covonia dry cough) 福尔可定</li>
<li>Dextromethorphan (Benylin dry cough, Covonia original, Robitussin dry cough) 右美沙芬</li>
<li>Codeine linctus – Adults - more historic (abuse potential) 可待因止咳糖浆</li>
<li>Sedative antihistamines - diphenhydramine 苯海拉明</li>
</ul>
</li>
</ul>
<h4 id="Colds">Colds</h4>
<h5 id="Red-Flags-3">Red Flags</h5>
<ul>
<li>Ear pain</li>
<li>Muscle ache/chills/fatigue/dry cough and vulnerable group</li>
<li>Pain on inspiration</li>
<li>Wheezing</li>
<li>Shortness of breath</li>
</ul>
<p>Timescale for referral: 2 weeks</p>
<h5 id="Product-selection-3">Product selection</h5>
<ul>
<li>
<p>Oral analgesics (+ caffeine/vit c)</p>
<ul>
<li>Paracetamol (Panadol, Calpol)</li>
<li>Aspirin (Disprin, Beechams powders)</li>
<li>NSAIDS i.e. Ibuprofen (Nurofen, Cuprofen)</li>
</ul>
</li>
<li>
<p>Used in combination with opioids:</p>
<ul>
<li>Potential for addiction – 3 days max</li>
<li>Codeine (co-codamol, Solpadeine Max) 可待因</li>
<li>Dihydrocodeine (Paramol) 双氢可待因</li>
</ul>
</li>
<li>
<p>Inhalations</p>
<ul>
<li>Eucalyptus oil/Vicks/Carvol/Olbas oil</li>
</ul>
</li>
<li>
<p>Decongestants (systemic Vs topical)</p>
<ul>
<li>Be aware of contra indications!!</li>
<li>Max 7 days treatment</li>
<li>Pseudoephedrine/Phenylephrine – systemic 伪麻黄碱/苯肾上腺素</li>
<li>Oxymetazoline/Xylometazoline - topical 羟甲唑啉/赛洛唑啉</li>
</ul>
</li>
<li>
<p>Combination products (analgesic/decongestant/cough)</p>
<ul>
<li>E.g. night nurse/day nurse/covonia cold and flu</li>
<li>These can be useful – but check:
<ul>
<li>That all ingredients are needed and appropriate</li>
<li>Drowsiness s/e’s with antihistamine</li>
</ul>
</li>
</ul>
</li>
</ul>
<h4 id="Hay-fever-seasonal-allergic-rhinitis">Hay fever (seasonal allergic rhinitis)</h4>
<h5 id="Red-Flags-4">Red Flags</h5>
<ul>
<li>Unilateral nasal blockage 单侧鼻塞</li>
<li>Muscle ache/chills/fatigue/dry cough and vulnerable group 肌肉酸痛/畏寒/疲劳/干咳以及易感人群</li>
</ul>
<p>Timescale for referral: 2 weeks</p>
<h5 id="Product-selection-4">Product selection</h5>
<ul>
<li>Oral antihistamines 口服抗组胺药
<ul>
<li>Non drowsy – adults and children
<ul>
<li>Loratadine tabs 6+/syrup 2+ 氯雷他定</li>
<li>Cetirizine tabs 12+/syrup 2+ 西替利嗪</li>
<li>Acrivastine capsules 12+ 阿克拉维斯汀</li>
</ul>
</li>
<li>Drowsy - adults and children
<ul>
<li>Chlorphenamine tabs 6+/syrup 1+ 氯苯那敏</li>
</ul>
</li>
</ul>
</li>
<li>Steroid Nasal sprays 类固醇鼻喷雾剂
<ul>
<li>Over 18’s only</li>
<li>Most effective for nasal symptoms, not immediate action</li>
<li>Beclometasone 倍氯米松</li>
<li>Fluticasone 氟替卡松</li>
<li>Budesonide 布地奈德</li>
<li>Mometasone 莫米松</li>
<li>Triamcinolone 曲安奈德</li>
</ul>
</li>
<li>Eye drops 眼药水
<ul>
<li>Sodium cromoglicate 6+ 色甘酸钠</li>
</ul>
</li>
<li>Decongestant tablets 减充血剂片剂
<ul>
<li>Pseudoephedrine tabs (Remember contra-indications!)</li>
</ul>
</li>
<li>Other nasal sprays
<ul>
<li>Decongestant nasal sprays 减充血剂鼻喷剂
<ul>
<li>Oxymetazoline/Xylometazoline Max 7 days – rebound congestion</li>
</ul>
</li>
<li>Protectants 鼻腔保护剂
<ul>
<li>Prevalin</li>
</ul>
</li>
<li>Saline 盐水</li>
</ul>
</li>
</ul>
<h2 id="Clinical-Skills">Clinical Skills</h2>
<h2 id="Law">Law</h2>
<h2 id="Core-Concept-Lectures">Core Concept Lectures</h2>
<h3 id="LECTURE7-01-Core-Concept-5-Interaction-of-pathogens">LECTURE7 01 Core Concept 5 Interaction of pathogens</h3>
<p>Lecturer: Gavin Humphreys</p>
<p>Date: Week 2</p>
<h4 id="1-Introduction-Key-Definitions">1. Introduction &amp; Key Definitions</h4>
<h5 id="Bacterial-Abundance">Bacterial Abundance</h5>
<ul>
<li><strong>Global Scale:</strong> There are estimated to be $10^{30}$ bacterial cells on Earth (more than stars in the observable universe).</li>
<li><strong>Human Scale:</strong> Bacterial cells in/on the human body outnumber eukaryotic cells by a ratio of approximately <strong>1.3 : 1</strong>.</li>
<li><strong>Location:</strong> The majority reside in the gut, but they also colonize the skin, nasal cavity, respiratory tract, etc.</li>
</ul>
<h5 id="Commensal-vs-Pathogen">Commensal vs. Pathogen</h5>
<ul>
<li><strong>Commensal Microbiota:</strong> Bacteria that normally live on/in a healthy host without causing harm.
<ul>
<li><strong>Functions/Benefits:</strong>
<ol>
<li><strong>Immune Development:</strong> Colonization from birth helps train the immune system.</li>
<li><strong>Colonisation Resistance:</strong> They occupy space and consume nutrients, preventing pathogens from establishing a stronghold.</li>
<li><strong>Metabolic Organ:</strong> They break down complex indigestible carbohydrates that humans cannot digest.</li>
</ol>
</li>
</ul>
</li>
<li><strong>Opportunistic Pathogen:</strong> Commensals that cause disease when the host’s immune system is compromised or when they enter a sterile site.</li>
<li><strong>Obligate Human Pathogen:</strong> Microorganisms that <em>must</em> cause disease to be transmitted and survive (e.g., <em>Neisseria gonorrhoeae</em>). They generally do not survive well outside the host.</li>
</ul>
<h5 id="Immunocompromised-States">Immunocompromised States</h5>
<p>Opportunistic infections occur when host defenses are breached:</p>
<ul>
<li><strong>Damage to Epithelia:</strong> Cuts, surgical wounds, eczema, burns.</li>
<li><strong>Disruption of Commensals:</strong> Overuse of antibiotics (e.g., leading to <em>C. difficile</em>).</li>
<li><strong>Immune Impairment:</strong> Flu/RSV infections, HIV/AIDS, chemotherapy.</li>
<li><strong>Foreign Devices:</strong> Catheters, prosthetic joints (no blood supply/immune presence, prone to <strong>biofilm</strong> formation).</li>
</ul>
<h4 id="2-Transmission-of-Infection-Epidemiology">2. Transmission of Infection (Epidemiology)</h4>
<p>Bacteria spread via various routes. These routes often overlap.</p>
<h5 id="Horizontal-Transmission-Person-to-Person-Environment-to-Person">Horizontal Transmission (Person-to-Person / Environment-to-Person)</h5>
<ol>
<li><strong>Aerosol/Airborne:</strong> Droplets from coughing/sneezing (e.g., Influenza, COVID-19).
<ul>
<li><em>Small droplets:</em> Stay suspended in air, travel through ventilation.</li>
<li><em>Large droplets:</em> Fall within ~2 meters, contaminating surfaces.</li>
</ul>
</li>
<li><strong>Direct Contact:</strong> Skin-to-skin contact (e.g., unwashed hands of healthcare workers).</li>
<li><strong>Fomite:</strong> Inanimate objects that transfer infection (e.g., mobile phones, keyboards, door handles).</li>
<li><strong>Vehicle:</strong> Contaminated food or water.</li>
<li><strong>Vector:</strong> Living organisms (arthropods) that transmit disease (e.g., mosquitoes).</li>
</ol>
<h5 id="Vertical-Transmission-Parent-to-Child">Vertical Transmission (Parent-to-Child)</h5>
<ul>
<li><strong>Via Placenta:</strong> During pregnancy.</li>
<li><strong>During Birth:</strong> Contact with vaginal canal (e.g., <em>Gonorrhea</em> conjunctivitis).</li>
<li><strong>Via Breast Milk.</strong></li>
</ul>
<h4 id="3-Virulence-Factors">3. Virulence Factors</h4>
<p>To cause disease, bacteria produce <strong>Virulence Factors</strong>. These are strategies to:</p>
<ol>
<li>Promote <strong>Colonisation &amp; Invasion</strong>.</li>
<li>Cause <strong>Host Damage</strong> (Toxicity).</li>
<li>Enable <strong>Immune Evasion</strong>.</li>
</ol>
<h5 id="A-Adhesion-Motility">A. Adhesion &amp; Motility</h5>
<p>The first step in infection is attaching to a surface to prevent being washed away.</p>
<ul>
<li><strong>Fimbriae</strong> / <strong>Pili:</strong>
<ul>
<li>Short, hair-like protein appendages anchored to the outer membrane.</li>
<li><strong>Function:</strong>
<ul>
<li><strong>Intimate Attachment:</strong> Adhesins at the tip bind specific host receptors.</li>
<li><strong>Twitching Motility:</strong> Extend, attach, and retract to drag the bacteria along a surface (“force-driven contraction”).</li>
<li><strong>Biofilm Formation:</strong> Aid in aggregation.</li>
</ul>
</li>
</ul>
</li>
<li><strong>Flagella:</strong>
<ul>
<li>Long, rigid, corkscrew-like structures.</li>
<li><strong>Function:</strong> Motility (movement). Powered by a proton motor to rotate.</li>
<li><strong>Microbial Taxis:</strong> Movement towards nutrients or away from danger (toxins/UV).</li>
</ul>
</li>
</ul>
<h5 id="B-Immune-Evasion-Capsules">B. Immune Evasion: Capsules</h5>
<ul>
<li><strong>Structure:</strong> A polysaccharide layer surrounding the bacterial cell.</li>
<li><strong>Importance:</strong> Critical for <strong>invasive infections</strong> (survival in the blood, e.g., meningitis, pneumonia). Without a capsule, these bacteria are easily cleared.</li>
<li><strong>Mechanisms of Evasion:</strong>
<ol>
<li><strong>Charge Effect:</strong> Capsules often have a high <strong>negative charge</strong>. Since phagocytes are also negatively charged, electrostatic repulsion prevents phagocytosis.</li>
<li><strong>Mimicry:</strong> The capsule composition mimics host tissue (e.g., Hyaluronic acid), masking the bacteria from the immune system. (It coats itself in what the immune system thinks is host tissue <strong>(connective tissue)</strong>, so it doesn’t recognize it as an invading pathogen)</li>
</ol>
</li>
</ul>
<h6 id="Case-Study-Neisseria-meningitidis-Meningitis">Case Study: <em>Neisseria meningitidis</em> (Meningitis)</h6>
<ul>
<li><strong>Virulence:</strong> The capsule is the critical factor allowing survival in the blood (septicaemia) and crossing the blood-brain barrier (meningitis).</li>
<li><strong>Capsule Serotype B:</strong> Mimics host tissue (NCAM). This made vaccine development difficult (took ~30 years) because the immune system does not recognize it as foreign.</li>
<li><strong>Clinical Sign:</strong> <strong>Non-blanching rash</strong> caused by bacteria damaging capillaries and leaking blood.</li>
</ul>
<h5 id="4-Bacterial-Toxins-Host-Damage">4. Bacterial Toxins (Host Damage)</h5>
<p>Bacteria damage the host to obtain nutrients or spread.</p>
<h6 id="1-Endotoxins-Lipopolysaccharide-LPS">1. Endotoxins (Lipopolysaccharide - LPS)</h6>
<ul>
<li><strong>Origin:</strong> Innate part of the <strong>Gram-negative</strong> bacterial outer membrane (specifically <strong>Lipid A</strong>, a part of Lipopolysaccharide (LPS)).</li>
<li><strong>Release:</strong> Released only when the bacterial cell dies or lyses.</li>
<li><strong>Mechanism:</strong> Not site-specific.</li>
<li><strong>Effect:</strong> Highly immunogenic. Triggers a massive, uncontrolled inflammatory response (Cytokine storm, Complement activation).</li>
<li><strong>Outcome:</strong> Can lead to Septicemia / Sepsis.</li>
</ul>
<h6 id="2-Exotoxins">2. Exotoxins</h6>
<ul>
<li><strong>Origin:</strong> Proteins specifically produced and <strong>secreted</strong> by living bacteria (both Gram+ and Gram-).</li>
<li><strong>Mechanism:</strong> Site-specific; they travel through the blood to target specific distal organs or cells.</li>
<li><strong>Examples:</strong>
<ul>
<li><strong>Scalded Skin Syndrome (Staphylococcus):</strong> Toxin produced in the umbilicus/nose enters blood, travels to skin, and cleaves <strong>desmoglein</strong> (skin glue), causing skin to peel off.</li>
</ul>
</li>
</ul>
<h6 id="Case-Study-Pneumolysin-Streptococcus-pneumoniae">Case Study: Pneumolysin (<em>Streptococcus pneumoniae</em>)</h6>
<p>A pore-forming exotoxin targeting <strong>cholesterol</strong> in host cell membranes.</p>
<ul>
<li><strong>Target:</strong> Respiratory tract (causes Pneumonia).</li>
<li><strong>Action 1: Immunosuppressive (Early stage/Low conc):</strong>
<ul>
<li>Attacks the cholesterol receptor, and it will open up a pore randomly in membrane. Inhibits the <strong>mucociliary escalator</strong> (stops cilia beating), preventing clearance of bacteria.</li>
<li>Causes <strong>apoptosis</strong> (cell death) of resident macrophages.</li>
</ul>
</li>
<li><strong>Action 2: Pro-inflammatory (Late stage/High conc):</strong>
<ul>
<li>Recruits <strong>Neutrophils</strong> to the lungs.</li>
<li>While this sounds like a defense, the neutrophils release enzymes that cause massive <strong>tissue damage</strong> (consolidation in lungs), allowing bacteria to proliferate further.</li>
</ul>
</li>
<li><strong>Symptoms:</strong> Fever, malaise, dyspnoea (breathlessness), productive cough, crackles.</li>
</ul>
<h4 id="Summary-Table-Endotoxin-vs-Exotoxin">Summary Table: Endotoxin vs. Exotoxin</h4>
<table>
<thead>
<tr>
<th><strong>Feature</strong></th>
<th><strong>Endotoxin</strong></th>
<th><strong>Exotoxin</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Source</strong></td>
<td>Gram-negative bacteria only</td>
<td>Gram-positive &amp; Gram-negative</td>
</tr>
<tr>
<td><strong>Location</strong></td>
<td>Part of cell wall (LPS / Lipid A)</td>
<td>Secreted from the cell</td>
</tr>
<tr>
<td><strong>Release</strong></td>
<td>Upon cell death/lysis</td>
<td>Produced by living cells</td>
</tr>
<tr>
<td><strong>Specificity</strong></td>
<td>Non-specific (Systemic inflammation)</td>
<td>Highly specific targets (e.g., nerves, skin)</td>
</tr>
<tr>
<td><strong>Heat Stability</strong></td>
<td>Heat stable</td>
<td>Heat labile (usually proteins)</td>
</tr>
<tr>
<td><strong>Example</strong></td>
<td>Meningococcal Septicemia</td>
<td>Pneumolysin, Tetanus, Botulinum</td>
</tr>
</tbody>
</table>
<h3 id="LECTURE9-01-Core-Concept-7-Overview-of-Immunity">LECTURE9 01 Core Concept 7 Overview of Immunity</h3>
<p>Lecturer: Dr. Costas Demonacos</p>
<p>Date: Week 2</p>
<h4 id="1-Introduction-to-the-Immune-System-免疫系统简介">1. Introduction to the Immune System (免疫系统简介)</h4>
<h5 id="Role-Function">Role &amp; Function</h5>
<p>The immune system’s primary role is to provide <strong>defense (防御)</strong> against various pathogens (bacteria, viruses, parasites, fungi).</p>
<ul>
<li><strong>Beneficial (有益):</strong>
<ul>
<li>Protection from Invaders (防御外来入侵).</li>
<li>Elimination of Altered Self (e.g., cancer cells) (清除自身变异细胞).</li>
</ul>
</li>
<li><strong>Detrimental (有害/副作用):</strong>
<ul>
<li>Discomfort (Inflammation) (不适/炎症).</li>
<li>Damage to self (Autoimmunity) (自身免疫损伤).</li>
</ul>
</li>
</ul>
<h5 id="Two-Major-Elements">Two Major Elements</h5>
<table>
<thead>
<tr>
<th><strong>Feature</strong></th>
<th><strong>Innate Immune System (先天性免疫系统)</strong></th>
<th><strong>Adaptive Immune System (适应性免疫系统)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Response Time</strong></td>
<td>Rapidly evoked (First line of defense) (快速响应)</td>
<td>Slow activation (慢速激活)</td>
</tr>
<tr>
<td><strong>Specificity</strong></td>
<td>Non-specific (非特异性)</td>
<td>Highly specific (高度特异性)</td>
</tr>
<tr>
<td><strong>Memory</strong></td>
<td>No memory (无记忆)</td>
<td>Immunological memory (免疫记忆)</td>
</tr>
<tr>
<td><strong>Development</strong></td>
<td>Present from birth (与生俱来)</td>
<td>Developed/Refined over time (后天获得)</td>
</tr>
</tbody>
</table>
<h4 id="2-Cells-of-the-Immune-System-免疫细胞">2. Cells of the Immune System (免疫细胞)</h4>
<p>Immune cells originate from <strong>Hematopoietic stem cells (造血干细胞)</strong> and differentiate into two main lineages: <strong>Myeloid (髓系)</strong> and <strong>Lymphoid (淋巴系)</strong>.</p>
<h5 id="A-Myeloid-Lineage-Innate-Immunity-mostly-髓系细胞-主要负责先天免疫">A. Myeloid Lineage (Innate Immunity mostly) (髓系细胞 - 主要负责先天免疫)</h5>
<ol>
<li><strong>Antigen Presenting Cells (APCs) (抗原提呈细胞):</strong>
<ul>
<li><em>Function:</em> Capture, process, and present antigens to adaptive immune cells (T cells). This bridges innate and adaptive immunity.</li>
<li><strong>Macrophages (巨噬细胞):</strong> Phagocytose (吞噬) pathogens, break them down, and present peptides.</li>
<li><strong>Dendritic Cells (DCs) (树突状细胞):</strong> “Professional” APCs. Located in tissues (skin, mucosa), capture antigens, and transport them to lymph nodes to activate T cells.</li>
<li>B cells as well that can be antigen presenting cells</li>
</ul>
</li>
<li><strong>Granulocytes (粒细胞):</strong>
<ul>
<li><strong>Neutrophils (中性粒细胞):</strong>
<ul>
<li>Main defense against <strong>rapidly dividing bacteria (快速分裂的细菌)</strong>.</li>
<li>First to migrate to infection sites (Chemotaxis).</li>
<li>Mechanism: Phagocytosis and destruction.</li>
</ul>
</li>
<li><strong>Basophils (嗜碱性粒细胞):</strong>
<ul>
<li>Produce different granules which contain several chemicals that attack foreign microorganisms, the contents of the granules are enzymes and proteins and so on which can then eliminate microorganisms.</li>
<li>Release <strong>Histamine (组胺)</strong>.</li>
<li>Active in <strong>allergic reactions (过敏反应)</strong>.</li>
</ul>
</li>
<li><strong>Eosinophils (嗜酸性粒细胞):</strong>
<ul>
<li>Similar to basopils</li>
<li>Release toxins to kill <strong>parasites (worms/protozoa) (寄生虫)</strong>.</li>
<li>Involved in allergic asthma.</li>
<li>Release <strong>Histamine</strong>.</li>
</ul>
</li>
<li><strong>Mast Cells (肥大细胞):</strong>
<ul>
<li>Concentrated under body surfaces (skin, mucosa).</li>
<li>Release factors causing <strong>vasodilation (血管扩张)</strong> and increased permeability (inflammation).</li>
</ul>
</li>
</ul>
</li>
<li><strong>Natural Killer (NK) Cells (自然杀伤细胞):</strong>
<ul>
<li><em>Note:</em> Part of the <strong>Innate</strong> system despite lymphoid origin.</li>
<li><em>Target:</em> <strong>Virus-infected cells (病毒感染细胞)</strong> and <strong>Cancer cells (癌细胞)</strong>.</li>
<li><em>Mechanism:</em> Recognize cells with low <strong>MHC Class I (主要组织相容性复合体 I类)</strong> expression. (Healthy cells inhibit NK cells via MHC I; infected/tumor cells often lose MHC I to hide, thus triggering NK killing).</li>
<li>the natural killer cells have two receptors, <strong>the activating receptor</strong> and <strong>the repressive receptor</strong>.</li>
</ul>
</li>
</ol>
<table>
<thead>
<tr>
<th><strong>Component of innate immunity</strong></th>
<th><strong>Main mechanisms of action</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Mast cells (concentrated under the body  surfaces)</td>
<td>Release factors which increase blood  flow and vascular permeability bringing components of immunity to the site of  infection</td>
</tr>
<tr>
<td>Neutrophils and macrophages  (phagocytes)</td>
<td>Engulf (phagocytose) and destroy  micro-organisms</td>
</tr>
<tr>
<td>Eosinophils</td>
<td>Secrete factors which kill protozoa and  worms</td>
</tr>
<tr>
<td>Natural killer cells</td>
<td>Destroy virus infected cells</td>
</tr>
<tr>
<td>Cytokines - interferon</td>
<td>Toxic to viruses</td>
</tr>
</tbody>
</table>
<h5 id="B-Lymphoid-Lineage-Adaptive-Immunity-mostly-淋巴系细胞-主要负责适应性免疫">B. Lymphoid Lineage (Adaptive Immunity mostly) (淋巴系细胞 - 主要负责适应性免疫)</h5>
<ol>
<li><strong>T Lymphocytes (T Cells) (T 淋巴细胞):</strong>
<ul>
<li><strong>CD4+ T Helper Cells (</strong>$T_H$<strong>) (辅助性 T 细胞):</strong>
<ul>
<li>Recognize antigen on <strong>MHC Class II (MHC II类分子)</strong> (Macrophages, dendritic cells and B cells<br>
which are antigen presenting cells<br>
present antigen on <strong>MHC Class II</strong>).</li>
<li><strong>Th1:</strong> Stimulate Cell-Mediated Immunity (CMI) (细胞免疫).</li>
<li><strong>Th2:</strong> Stimulate B cells to produce antibodies (Humoral Immunity) (体液免疫).</li>
</ul>
</li>
<li><strong>CD8+ Cytotoxic T Cells (</strong>$T_C$<strong>) (细胞毒性 T 细胞):</strong>
<ul>
<li>Recognize antigen on <strong>MHC Class I (MHC I类分子)</strong> (present on all nucleated cells).</li>
<li>Directly kill infected/abnormal cells by producing enzymes and molecules, chemicals that are cytotoxic (Cytotoxicity).</li>
</ul>
</li>
</ul>
</li>
<li><strong>B Lymphocytes (B Cells) (B 淋巴细胞):</strong>
<ul>
<li>Differentiate into <strong>Plasma Cells (浆细胞)</strong>.</li>
<li>Produce <strong>Antibodies (Immunoglobulins, Ig) (抗体/免疫球蛋白)</strong>.</li>
</ul>
</li>
</ol>
<h4 id="3-Antibody-Structure-Function-抗体结构与功能">3. Antibody Structure &amp; Function (抗体结构与功能)</h4>
<ul>
<li><strong>Structure:</strong> Y-shaped.
<ul>
<li><strong>Fab region (Amino terminal):</strong> Recognizes and binds to specific <strong>Antigen (抗原)</strong>.</li>
<li><strong>Fc region (Carboxy terminal):</strong> Binds to receptors on immune cells (recruitment).</li>
<li>The <strong>amino terminal end</strong>, the top part of the antibody, recognizes the antigen whereas the bottom part, the <strong>carboxy terminal end</strong>, binds to receptors that exist on cells of the immune system.</li>
</ul>
</li>
<li><strong>Functions:</strong>
<ol>
<li><strong>Opsonisation (识别作用):</strong> Coating pathogens to make them “visible” and easier for phagocytes to eat.</li>
<li><strong>Neutralisation (中和作用):</strong> Binding to toxins or viruses to prevent them from entering/damaging cells.</li>
<li><strong>Complement Activation (补体激活):</strong> Triggering the complement cascade to form a “tube” (Membrane Attack Complex) that punches holes in bacteria.</li>
<li><strong>ADCC (Antibody-Dependent Cellular Cytotoxicity) (抗体依赖性细胞介导的细胞毒性):</strong> Recruiting cells (like NK cells) to kill targets bound by antibodies.</li>
</ol>
</li>
<li><strong>Classes of Immunoglobulins:</strong>
<ul>
<li><strong>IgM:</strong> First produced, produced from activated B lymphocytes.</li>
<li><strong>IgG:</strong> Main antibody in circulation; long-term immunity；  produced by B cells that are differentiated by the <strong>interferon gamma (γ干扰素)</strong>.</li>
<li><strong>IgA:</strong> Mucosal immunity; passed to infants via breast milk.</li>
<li><strong>IgE:</strong> Involved in <strong>Allergy (过敏)</strong> and parasitic infections.</li>
</ul>
</li>
</ul>
<h5 id="Immunological-Memory-免疫记忆">Immunological Memory (免疫记忆)</h5>
<ul>
<li><strong>Primary Response (初次应答):</strong> Slow (lag phase ~12 days), lower magnitude.</li>
<li><strong>Secondary Response (二次应答):</strong> Fast (lag phase ~4 days), much stronger (robust), due to Memory B/T cells.</li>
</ul>
<h4 id="4-Hypersensitivity-Allergy-超敏反应-过敏">4. Hypersensitivity (Allergy) (超敏反应/过敏)</h4>
<p>Hypersensitivity is an inappropriate immune response to benign antigens (allergens).</p>
<p><img src="https://raw.githubusercontent.com/thyzzs/Pic/main/image-20251202211255845.png" alt="image-20251202211255845"></p>
<h5 id="Type-I-Hypersensitivity-IgE-Mediated-I型超敏反应">Type I Hypersensitivity (IgE-Mediated) (I型超敏反应)</h5>
<p><img src="C:%5CUsers%5Cthyzz%5CAppData%5CRoaming%5CTypora%5Ctypora-user-images%5Cimage-20251202211628893.png" alt="image-20251202211628893"></p>
<ul>
<li><strong>Mechanism:</strong>
<ol>
<li>First exposure to allergen $\rightarrow$ Production of <strong>IgE</strong>.</li>
<li>IgE binds to <strong>Fc receptors</strong> on <strong>Mast Cells</strong> (Sensitization).</li>
<li>Subsequent exposure $\rightarrow$ Allergen cross-links IgE on mast cells.</li>
<li><strong>Degranulation (脱颗粒):</strong> Massive release of <strong>Histamine (组胺)</strong> and other vasoactive amines.</li>
</ol>
</li>
<li><strong>Symptoms:</strong> Vasodilation, itching, bronchoconstriction (Asthma), systemic anaphylaxis.</li>
<li>the production of IgE stimulates the mast cells to produce those allergens, which those vasoactive amines, which now cause all these undesirable effects on our body.</li>
<li><strong>allergies to pollen (花粉过敏)</strong></li>
</ul>
<h5 id="Treatment-Strategy">Treatment Strategy</h5>
<ul>
<li><strong>Antihistamines (抗组胺药):</strong> Block histamine receptors to prevent symptoms (do not stop the release, just the effect).</li>
</ul>
<h4 id="Summary-Table-Innate-vs-Adaptive-Cells">Summary Table: Innate vs. Adaptive Cells</h4>
<table>
<thead>
<tr>
<th><strong>Cell Type</strong></th>
<th><strong>Lineage</strong></th>
<th><strong>System</strong></th>
<th><strong>Main Function</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Neutrophil</strong></td>
<td>Myeloid</td>
<td>Innate</td>
<td>Phagocytosis (Bacteria)</td>
</tr>
<tr>
<td><strong>Macrophage</strong></td>
<td>Myeloid</td>
<td>Innate</td>
<td>Phagocytosis + Antigen Presentation</td>
</tr>
<tr>
<td><strong>Dendritic Cell</strong></td>
<td>Myeloid</td>
<td>Innate</td>
<td>Professional Antigen Presentation</td>
</tr>
<tr>
<td><strong>NK Cell</strong></td>
<td>Lymphoid</td>
<td>Innate</td>
<td>Kill virus/cancer cells (low MHC I)</td>
</tr>
<tr>
<td><strong>B Cell</strong></td>
<td>Lymphoid</td>
<td>Adaptive</td>
<td>Produce Antibodies (Humoral)</td>
</tr>
<tr>
<td><strong>T Helper (CD4)</strong></td>
<td>Lymphoid</td>
<td>Adaptive</td>
<td>Coordinate response (Cytokines)</td>
</tr>
<tr>
<td><strong>Cytotoxic T (CD8)</strong></td>
<td>Lymphoid</td>
<td>Adaptive</td>
<td>Kill infected cells (Cellular)</td>
</tr>
</tbody>
</table>
<h3 id="LECTURE11-01-Core-Concept-9-Antimicrobial-Mechanisms">LECTURE11 01 Core Concept 9 Antimicrobial Mechanisms</h3>
<p>Lecturer: Richard Bryce</p>
<h4 id="1-Introduction-to-Microorganisms-Selective-Toxicity">1. Introduction to Microorganisms &amp; Selective Toxicity</h4>
<h5 id="Microbes-Microbiota">Microbes &amp; Microbiota</h5>
<ul>
<li><strong>Microbiota (微生物群):</strong> Microbes living in and around the body (e.g., intestines). 95% located in the GI tract.</li>
<li><strong>Microbiome (微生物组):</strong> The genetic material of all these micro-organisms.</li>
<li><strong>Pathogenic (致病的):</strong> Causing disease vs. Beneficial (Beneficial flora).</li>
</ul>
<h5 id="Selective-Inhibition-选择性抑制">Selective Inhibition (选择性抑制)</h5>
<p>To safely treat infections, drugs must target structures or processes unique to bacteria (prokaryotes) that are absent or different in humans (eukaryotes).</p>
<p><strong>Key Bacterial Targets:</strong></p>
<ol>
<li><strong>Outside:</strong>
<ul>
<li><strong>Cell Wall (细胞壁):</strong> Peptidoglycan (肽聚糖) structure.</li>
<li><strong>Cell Membrane (细胞膜):</strong> Plasma membrane.</li>
</ul>
</li>
<li><strong>Inside:</strong>
<ul>
<li><strong>Circular DNA (环状 DNA):</strong> And plasmids.</li>
<li><strong>Ribosomes (核糖体):</strong> 70S (50S + 30S), unlike human 80S.</li>
<li><strong>Metabolic Pathways (代谢途径):</strong> Unique enzymes (e.g., folate synthesis).</li>
</ul>
</li>
</ol>
<h5 id="Gram-positive-vs-Gram-negative-Bacteria">Gram-positive vs. Gram-negative Bacteria</h5>
<ul>
<li><strong>Gram-positive (革兰氏阳性菌):</strong> Thick peptidoglycan layer, no outer membrane.</li>
<li><strong>Gram-negative (革兰氏阴性菌):</strong> Thin peptidoglycan layer, has an <strong>Outer Membrane (外膜)</strong> containing Lipopolysaccharides (LPS).</li>
</ul>
<h4 id="2-Target-1-Bacterial-DNA-细菌-DNA">2. Target #1: Bacterial DNA (细菌 DNA)</h4>
<h5 id="The-Problem-DNA-Compaction">The Problem: DNA Compaction</h5>
<ul>
<li>Bacterial DNA is circular and very long (~1300 μm). It must fit into a tiny cell.</li>
<li><strong>Supercoiling (超螺旋):</strong> The DNA double helix is twisted into a superhelix to compact it.
<ul>
<li><strong>Negative Supercoiling (负超螺旋):</strong> Left-handed coiling. Loosens strands for replication/transcription. Most common.</li>
<li><strong>Positive Supercoiling (正超螺旋):</strong> Right-handed. Found in thermophiles to prevent denaturation.</li>
</ul>
</li>
</ul>
<h5 id="The-Enzymes-Topoisomerases-拓扑异构酶">The Enzymes: Topoisomerases (拓扑异构酶)</h5>
<ul>
<li><strong>DNA Gyrase (DNA 促旋酶):</strong> Introduces negative supercoils. Essential in <strong>Gram-negative</strong> bacteria.</li>
<li><strong>Topoisomerase IV (拓扑异构酶 IV):</strong> Essential in <strong>Gram-positive</strong> bacteria.</li>
<li><strong>Mechanism:</strong> Cuts one DNA region $\rightarrow$ Passes another region through the break $\rightarrow$ Reseals the break.</li>
</ul>
<h5 id="Drug-Class-1-Quinolones-喹诺酮类">Drug Class 1: Quinolones (喹诺酮类)</h5>
<p>These are <strong>DNA Gyrase Inhibitors</strong>.</p>
<ul>
<li><strong>1st Generation:</strong> <strong>Nalidixic acid (萘啶酸)</strong> (1962).
<ul>
<li>Mainly active against Gram-negative.</li>
<li>Used for UTIs (Urinary Tract Infections).</li>
<li><strong>Bacteriocidal (杀菌的):</strong> Irreversible inhibition.</li>
</ul>
</li>
<li><strong>2nd Generation (Fluoroquinolones):</strong> <strong>Ciprofloxacin (环丙沙星)</strong> (1980).
<ul>
<li>Fluorine atom added (Fluoro-).</li>
<li>Increased Gram-positive activity.</li>
</ul>
</li>
<li><strong>3rd Generation:</strong> <strong>Levofloxacin (左氧氟沙星)</strong> (1993).
<ul>
<li>Active against Streptococci (e.g., <em>S. pneumoniae</em>).</li>
<li>“Broad spectrum” (广谱).</li>
</ul>
</li>
</ul>
<h5 id="Drug-Class-2-Nitroimidazoles-硝基咪唑类">Drug Class 2: Nitroimidazoles (硝基咪唑类)</h5>
<ul>
<li><strong>Example:</strong> <strong>Metronidazole (甲硝唑)</strong>.</li>
<li><strong>Mechanism (DNA Strand Breaking):</strong>
<ol>
<li>Requires <strong>Anaerobic environment (厌氧环境)</strong> to activate.</li>
<li>Nitro group ($-NO_2$) is reduced by bacterial electron transport to a <strong>Nitro radical anion</strong>.</li>
<li>Forms a toxic radical that extracts hydrogen from DNA, causing strand breaks (“Fireworks”).</li>
</ol>
</li>
<li><strong>Clinical Use:</strong> Anaerobic infections (e.g., <em>C. difficile</em>, Bacterial Vaginosis) and Protozoa.</li>
<li><strong>Side Effect:</strong> Alcohol intolerance (Disulfiram-like reaction).</li>
</ul>
<h4 id="3-Target-2-Protein-Synthesis-Ribosomes">3. Target #2: Protein Synthesis (Ribosomes)</h4>
<p><strong>Key Difference:</strong> Bacteria use <strong>70S Ribosomes</strong> (30S small subunit + 50S large subunit). Humans use 80S.</p>
<ul>
<li>Inhibition is usually <strong>Bacteriostatic (抑菌的)</strong> (stops growth, doesn’t kill).</li>
</ul>
<h5 id="The-Translation-Process-Drug-Targets">The Translation Process &amp; Drug Targets</h5>
<ol>
<li><strong>Initiation (起始):</strong> Subunits bind mRNA.
<ul>
<li><em>Inhibitor:</em> <strong>Oxazolidinones (e.g., Linezolid)</strong>. Binds 50S, prevents formation of the initiation complex (70S).</li>
</ul>
</li>
<li><strong>Elongation (延伸):</strong>
<ul>
<li>tRNA binding (A-site). <em>Inhibitor:</em> <strong>Tetracyclines</strong>.</li>
<li>Peptide bond formation (Peptidyl transferase). <em>Inhibitor:</em> <strong>Chloramphenicol</strong>.</li>
<li>Translocation (Moving A to P). <em>Inhibitor:</em> <strong>Macrolides</strong>.</li>
</ul>
</li>
<li><strong>Termination (终止).</strong></li>
</ol>
<h5 id="Drug-Classes">Drug Classes</h5>
<h6 id="A-Oxazolidinones-恶唑烷酮类">A. Oxazolidinones (恶唑烷酮类)</h6>
<ul>
<li><strong>Example:</strong> <strong>Linezolid (利奈唑胺)</strong>.</li>
<li><strong>Action:</strong> Binds <strong>50S</strong> subunit. Blocks initiation.</li>
<li><strong>Use:</strong> “Reserve” antibiotic for multi-resistant Gram-positive bacteria (e.g., <strong>MRSA</strong>, VRE).</li>
</ul>
<h6 id="B-Tetracyclines-四环素类">B. Tetracyclines (四环素类)</h6>
<ul>
<li><strong>Example:</strong> <strong>Tetracycline</strong>.</li>
<li><strong>Action:</strong> Binds <strong>30S</strong> subunit. Blocks aminoacyl-tRNA binding (A-site).</li>
<li><strong>Use:</strong> Acne, Lyme disease, Malaria.</li>
<li><strong>Contraindication:</strong> Children (Stains developing teeth/bones).</li>
</ul>
<h6 id="C-Macrolides-大环内酯类">C. Macrolides (大环内酯类)</h6>
<ul>
<li><strong>Example:</strong> <strong>Erythromycin (红霉素)</strong>.</li>
<li><strong>Action:</strong> Binds <strong>50S</strong> subunit near the exit tunnel. Blocks <strong>Translocation (易位)</strong> and peptide exit.</li>
<li><strong>Use:</strong> Gram-positive infections (Penicillin-allergic patients), Respiratory infections.</li>
</ul>
<h6 id="D-Chloramphenicol-氯霉素">D. Chloramphenicol (氯霉素)</h6>
<ul>
<li><strong>Action:</strong> Binds <strong>50S</strong> subunit. Inhibits <strong>Peptidyl Transferase (肽基转移酶)</strong> (peptide bond formation).</li>
<li><strong>Note:</strong> Competes with Macrolides (cannot use together).</li>
<li><strong>Use:</strong> Eye/Ear infections (drops), Typhoid.</li>
<li><strong>Toxicity:</strong> Bone marrow toxicity (avoid in infants - “Grey baby syndrome”).</li>
</ul>
<h4 id="4-Target-3-Metabolism-Folate-Pathway">4. Target #3: Metabolism (Folate Pathway)</h4>
<p><strong>Why Folate?</strong> Folate (Vitamin B9) is essential for synthesizing DNA bases (thymidine).</p>
<ul>
<li><strong>Humans:</strong> Absorb folate from diet (cannot synthesize it).</li>
<li><strong>Bacteria:</strong> Must synthesize folate <em>de novo</em> (cannot absorb it). <strong>Selective Target!</strong></li>
</ul>
<h5 id="The-Pathway-Inhibitors-Antimetabolites-抗代谢物">The Pathway &amp; Inhibitors (Antimetabolites - 抗代谢物)</h5>
<ol>
<li><strong>Step 1: PABA</strong> $\rightarrow$ <strong>Dihydropteroate</strong>
<ul>
<li><strong>Enzyme:</strong> <strong>DHPS</strong> (Dihydropteroate synthase). Unique to bacteria.</li>
<li><strong>Inhibitor:</strong> <strong>Sulfonamides (Sulfa drugs)</strong> e.g., <strong>Sulfamethoxazole</strong>.</li>
<li><strong>Mechanism:</strong> Mimics the substrate <strong>PABA</strong> (p-aminobenzoic acid). Competitive inhibition.</li>
<li><strong>SAR (Structure-Activity Relationship):</strong> Requires aromatic ring with para-amino group ($p-NH_2$). Secondary sulphonamide group ($pK_a$ 5-8) improves activity.</li>
</ul>
</li>
<li><strong>Step 2: Dihydrofolate</strong> $\rightarrow$ <strong>Tetrahydrofolate</strong>
<ul>
<li><strong>Enzyme:</strong> <strong>DHFR</strong> (Dihydrofolate reductase). Present in humans too, but bacterial enzyme is structurally different.</li>
<li><strong>Inhibitor:</strong> <strong>Trimethoprim (甲氧苄啶)</strong>.</li>
<li><strong>Mechanism:</strong> Mimics the <strong>Pteridine ring (蝶啶环)</strong> of folate. 100,000x more selective for bacterial DHFR.</li>
</ul>
</li>
</ol>
<h5 id="Combination-Therapy-Co-trimoxazole-复方新诺明-Septrim">Combination Therapy: Co-trimoxazole (复方新诺明/Septrim)</h5>
<ul>
<li><strong>Combination:</strong> <strong>Sulfamethoxazole + Trimethoprim</strong>.</li>
<li><strong>Concept:</strong> <strong>Sequential Blocking (序贯阻断)</strong>. Hits two enzymes in the same pathway.</li>
<li><strong>Benefit:</strong> Synergistic effect, lower doses required, reduces resistance.</li>
<li><strong>Use:</strong> UTIs, <em>Pneumocystis</em> pneumonia (in AIDS).</li>
</ul>
<h4 id="Summary-Table-Drug-Mechanisms">Summary Table: Drug Mechanisms</h4>
<table>
<thead>
<tr>
<th><strong>Drug Class</strong></th>
<th><strong>Target Site</strong></th>
<th><strong>Specific Mechanism</strong></th>
<th><strong>Effect</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Quinolones</strong></td>
<td>DNA Gyrase / Topo IV</td>
<td>Prevents supercoiling (DNA replication)</td>
<td>Bacteriocidal</td>
</tr>
<tr>
<td><strong>Nitroimidazoles</strong></td>
<td>DNA Structure</td>
<td>Free radicals break DNA strands</td>
<td>Bacteriocidal</td>
</tr>
<tr>
<td><strong>Oxazolidinones</strong></td>
<td>50S Ribosome</td>
<td>Prevents Initiation complex</td>
<td>Bacteriostatic</td>
</tr>
<tr>
<td><strong>Tetracyclines</strong></td>
<td>30S Ribosome</td>
<td>Blocks tRNA binding (A-site)</td>
<td>Bacteriostatic</td>
</tr>
<tr>
<td><strong>Macrolides</strong></td>
<td>50S Ribosome</td>
<td>Blocks Translocation / Exit tunnel</td>
<td>Bacteriostatic</td>
</tr>
<tr>
<td><strong>Chloramphenicol</strong></td>
<td>50S Ribosome</td>
<td>Inhibits Peptidyl transferase</td>
<td>Bacteriostatic</td>
</tr>
<tr>
<td><strong>Sulfonamides</strong></td>
<td>DHPS Enzyme</td>
<td>Mimics PABA (Folate synthesis)</td>
<td>Bacteriostatic</td>
</tr>
<tr>
<td><strong>Trimethoprim</strong></td>
<td>DHFR</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<h3 id="LECTURE12-01-Core-Concept-10-Beta-Lactam-agents">LECTURE12 01 Core Concept 10 Beta-Lactam agents</h3>
<p>Lecturer: Richard Bryce</p>
<h4 id="1-Introduction-Targets-引言与靶点">1. Introduction &amp; Targets (引言与靶点)</h4>
<p>Following the previous lecture on intracellular targets (DNA, Ribosomes), this lecture focuses on external targets unique to bacteria:</p>
<ol>
<li><strong>Cell Wall (细胞壁)</strong>: Synthesis inhibition.</li>
<li><strong>Cell Membrane (细胞膜)</strong>: Disruption.</li>
</ol>
<h4 id="2-Target-4-Bacterial-Cell-Wall-Synthesis-细菌细胞壁合成">2. Target #4: Bacterial Cell Wall Synthesis (细菌细胞壁合成)</h4>
<h5 id="The-Target-Peptidoglycan-肽聚糖">The Target: Peptidoglycan (肽聚糖)</h5>
<ul>
<li><strong>Function:</strong> Provides mechanical strength to withstand high internal <strong>osmotic pressure (渗透压)</strong>. Without it, the cell absorbs water and bursts (<strong>lysis/溶菌</strong>).</li>
<li><strong>Structure:</strong> A polymer mesh (“chicken wire”).
<ol>
<li><strong>Glycan chains (聚糖链):</strong> Alternating sugars <strong>NAM</strong> (N-acetylmuramic acid) and <strong>NAG</strong> (N-acetylglucosamine).</li>
<li><strong>Peptide cross-links (肽交联):</strong> Short peptides linking the sugar chains.</li>
</ol>
</li>
</ul>
<h5 id="Gram-Positive-vs-Gram-Negative-革兰氏阳性-vs-阴性">Gram-Positive vs. Gram-Negative (革兰氏阳性 vs 阴性)</h5>
<ul>
<li><strong>Gram-Positive (+):</strong> Thick peptidoglycan layer on the outside. Retains purple stain.</li>
<li><strong>Gram-Negative (-):</strong> Thin peptidoglycan layer sandwiched between an <strong>Inner Membrane</strong> and an <strong>Outer Membrane (外膜)</strong>. Drugs must pass through <strong>Porins (孔蛋白)</strong> to reach the cell wall.</li>
</ul>
<h5 id="The-Enzyme-Transpeptidase-转肽酶">The Enzyme: Transpeptidase (转肽酶)</h5>
<ul>
<li>Also known as <strong>Penicillin Binding Protein (PBP)</strong>.</li>
<li><strong>Mechanism:</strong> It catalyzes the cross-linking of peptide chains.
<ul>
<li>It connects <strong>D-Alanine</strong> to <strong>DAP</strong> (Diaminopimelic acid).</li>
<li><strong>Active Site:</strong> Contains a <strong>Serine (丝氨酸)</strong> residue that attacks the peptide to form the bond.</li>
</ul>
</li>
</ul>
<h4 id="3-Beta-Lactam-Antibiotics-Penicillins-青霉素类">3. Beta-Lactam Antibiotics: Penicillins (青霉素类)</h4>
<h5 id="Structure">Structure</h5>
<ul>
<li><strong>Beta-Lactam Ring (</strong>$\beta$<strong>-内酰胺环):</strong> A 4-membered cyclic amide. Highly strained (90° bond angles) and reactive.</li>
<li><strong>Thiazolidine Ring (噻唑烷环):</strong> 5-membered sulfur-containing ring.</li>
<li><strong>Key Features:</strong> Cis-protons, carboxylic acid, amide side chain.</li>
</ul>
<h5 id="Mechanism-of-Action-作用机制">Mechanism of Action (作用机制)</h5>
<ul>
<li><strong>Irreversible Inhibition (不可逆抑制):</strong> The Beta-lactam ring mimics the D-Ala-D-Ala substrate.</li>
<li>The <strong>Transpeptidase</strong> attacks the beta-lactam ring instead of the cell wall peptide.</li>
<li>The ring opens and forms a stable <strong>covalent</strong> bond <strong>(共价键)</strong> with the enzyme’s Serine residue.</li>
<li>The enzyme is permanently disabled $\rightarrow$ No cross-linking $\rightarrow$ Cell wall weakens $\rightarrow$ Cell lysis (<strong>Bactericidal/杀菌</strong>).</li>
</ul>
<h5 id="Penicillin-G-The-Original">Penicillin G (The Original)</h5>
<ul>
<li><strong>Limitations:</strong>
<ol>
<li><strong>Acid Sensitivity (酸敏感性):</strong> Destroyed by stomach acid (cannot be taken orally).</li>
<li><strong>Beta-Lactamase Sensitivity (</strong>$\beta$<strong>-内酰胺酶敏感性):</strong> Bacteria produce enzymes (Beta-lactamases) that break the ring.</li>
<li><strong>Narrow Spectrum (窄谱):</strong> Active mainly against Gram +ve; ineffective against <em>Staphylococci</em>.</li>
</ol>
</li>
</ul>
<h5 id="Drug-Development-Solving-the-Problems">Drug Development (Solving the Problems)</h5>
<h6 id="1-Solving-Acid-Sensitivity-Oral-Administration">1. Solving Acid Sensitivity (Oral Administration)</h6>
<ul>
<li><strong>Problem:</strong> The side chain carbonyl attacks the beta-lactam ring in acid.</li>
<li><strong>Solution:</strong> Add an <strong>Electron-Withdrawing</strong> Group <strong>(吸电子基团)</strong> (e.g., $NH_2$) to the side chain.</li>
<li><strong>Drug:</strong> <strong>Ampicillin (氨苄西林)</strong> / <strong>Amoxicillin (阿莫西林)</strong>.
<ul>
<li>Acid stable (can be taken orally).</li>
</ul>
</li>
</ul>
<h6 id="2-Solving-Beta-Lactamase-Resistance-Enzyme-Resistance">2. Solving Beta-Lactamase Resistance (Enzyme Resistance)</h6>
<ul>
<li><strong>Problem:</strong> Bacteria break the drug before it works.</li>
<li><strong>Solution:</strong> Add a <strong>Bulky Side Chain (大体积侧链)</strong> (Steric Shield) to block the Beta-lactamase from binding.</li>
<li><strong>Drugs:</strong>
<ul>
<li><strong>Methicillin (甲氧西林):</strong> Acid sensitive (must be injected).</li>
<li><strong>Oxacillin (苯唑西林) / Flucloxacillin:</strong> Acid stable &amp; Beta-lactamase resistant.</li>
</ul>
</li>
<li><em>Note:</em> <strong>MRSA</strong> (Methicillin-Resistant <em>S. aureus</em>) has mutated transpeptidases that don’t bind these drugs.</li>
</ul>
<h6 id="3-Increasing-Spectrum-Broad-Spectrum">3. Increasing Spectrum (Broad Spectrum)</h6>
<ul>
<li><strong>Hydrophobic side chains:</strong> Good for Gram-positive.</li>
<li><strong>Hydrophilic side chains:</strong> Better for Gram-negative (pass through porins).</li>
<li><strong>Drug:</strong> <strong>Carbenicillin (羧苄西林)</strong>.
<ul>
<li>Has a hydrophilic carboxyl group. Active against both Gram +ve and Gram -ve (e.g., <em>Pseudomonas</em>).</li>
</ul>
</li>
</ul>
<h4 id="4-Other-Beta-Lactams-其他-beta-内酰胺类">4. Other Beta-Lactams (其他 $\beta$-内酰胺类)</h4>
<h5 id="Cephalosporins-头孢菌素">Cephalosporins (头孢菌素)</h5>
<ul>
<li><strong>Structure:</strong> 6-membered dihydrothiazine ring (instead of 5-membered thiazolidine).</li>
<li><strong>Generations (1st - 4th):</strong> Developed to improve stability and Gram-negative activity.</li>
</ul>
<h5 id="Beta-Lactamase-Inhibitors-酶抑制剂">Beta-Lactamase Inhibitors (酶抑制剂)</h5>
<ul>
<li><strong>Clavulanic Acid (克拉维酸):</strong>
<ul>
<li>Structure looks like penicillin but has no antibacterial activity itself.</li>
<li><strong>Mechanism:</strong> “Suicide inhibitor”. It permanently binds to and inactivates Beta-lactamases.</li>
<li><strong>Usage:</strong> Combined with Amoxicillin (e.g., <strong>Augmentin / Co-amoxiclav</strong>). The Clavulanic acid sacrifices itself so Amoxicillin can kill the bacteria.</li>
</ul>
</li>
</ul>
<h4 id="5-Non-Beta-Lactam-Cell-Wall-Inhibitors">5. Non-Beta-Lactam Cell Wall Inhibitors</h4>
<h5 id="Vancomycin-万古霉素">Vancomycin (万古霉素)</h5>
<ul>
<li><strong>Structure:</strong> Huge Glycopeptide (Sugar + Peptide).</li>
<li><strong>Mechanism:</strong>
<ul>
<li>Does <strong>NOT</strong> bind to the enzyme (transpeptidase).</li>
<li>Binds to the <strong>Substrate (底物)</strong> (the D-Ala-D-Ala tail of the cell wall peptide) via Hydrogen bonds.</li>
<li>Acts as a physical barrier (“Samson in the temple”), preventing cross-linking.</li>
</ul>
</li>
<li><strong>Use:</strong> Serious Gram-positive infections (e.g., MRSA, <em>C. difficile</em>). Too big to pass Gram-negative outer membrane.</li>
<li><strong>Resistance:</strong> <strong>VRE/VRSA</strong> (Bacteria change the peptide from D-Ala-D-Ala to D-Ala-D-Lactate, so Vancomycin can’t bind).</li>
</ul>
<h4 id="6-Target-5-Cell-Membrane-细胞膜">6. Target #5: Cell Membrane (细胞膜)</h4>
<h5 id="Gramicidin-A-短杆菌肽-A">Gramicidin A (短杆菌肽 A)</h5>
<ul>
<li><strong>Structure:</strong> Peptide that coils into a helix.</li>
<li><strong>Mechanism:</strong> Two molecules dimerize in the membrane to form an <strong>Ion</strong> Channel <strong>(离子通道)</strong>.</li>
<li><strong>Effect:</strong> Uncontrolled flow of ions (e.g., $K^+, Na^+$) destroys ion gradients $\rightarrow$ Cell death.</li>
<li><strong>Toxicity:</strong> Can affect human cells too. Used only <strong>Topically (局部使用)</strong> (e.g., eye drops, creams).</li>
</ul>
<h4 id="Summary-Table">Summary Table</h4>
<table>
<thead>
<tr>
<th><strong>Drug Class</strong></th>
<th><strong>Target</strong></th>
<th><strong>Mechanism</strong></th>
<th><strong>Effect</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Penicillins</strong></td>
<td>Transpeptidase</td>
<td>Covalent binding to enzyme</td>
<td>Bactericidal</td>
</tr>
<tr>
<td><strong>Cephalosporins</strong></td>
<td>Transpeptidase</td>
<td>Covalent binding to enzyme</td>
<td>Bactericidal</td>
</tr>
<tr>
<td><strong>Clavulanic Acid</strong></td>
<td>Beta-Lactamase</td>
<td>Inhibits the enzyme that breaks penicillins</td>
<td>Protective</td>
</tr>
<tr>
<td><strong>Vancomycin</strong></td>
<td>D-Ala-D-Ala (Substrate)</td>
<td>Physically blocks cross-linking</td>
<td>Bactericidal</td>
</tr>
<tr>
<td><strong>Gramicidin A</strong></td>
<td>Cell Membrane</td>
<td>Forms ion pores</td>
<td>Bactericidal</td>
</tr>
</tbody>
</table>
<h3 id="LECTURE19-01-Core-Concept-16-Antimicrobial-resistance">LECTURE19 01 Core Concept 16 Antimicrobial resistance</h3>
<p>Lecturer: Andrew McBain (Transcript indicates guest delivery or recording)</p>
<h4 id="1-Introduction-Historical-Context-引言与历史背景">1. Introduction &amp; Historical Context (引言与历史背景)</h4>
<h5 id="The-“Post-Antibiotic-Era”-后抗生素时代">The “Post-Antibiotic Era” (后抗生素时代)</h5>
<ul>
<li><strong>Pre-Antibiotic Era (1900):</strong> The leading causes of death were infectious diseases (e.g., influenza, pneumonia, tuberculosis, gastroenteritis). Life expectancy was lower.</li>
<li><strong>Antibiotic Era (Present/Recent):</strong> Major causes of death shifted to non-communicable diseases (e.g., heart disease, cancer, stroke).</li>
<li><strong>Current Threat:</strong> We are approaching a “post-antibiotic era” where common infections could kill again due to resistance. Patients are already dying from infections with no suitable antibiotic treatment options.</li>
</ul>
<h5 id="Defining-Resistance-耐药性的定义">Defining Resistance (耐药性的定义)</h5>
<ul>
<li><strong>Definition:</strong> The <strong>acquired ability (获得性能力)</strong> of a microorganism to resist the effects of a chemotherapeutic agent to which it is normally sensitive.</li>
<li><strong>Crucial Concept:</strong> It is the <strong>microbe (microorganism)</strong> that becomes resistant, <strong>NOT the patient</strong>.
<ul>
<li><em>Note:</em> Do not say “The patient became resistant to penicillin.” Say “The bacteria infecting the patient became resistant.”</li>
</ul>
</li>
</ul>
<h4 id="2-Classifications-of-Resistance-耐药性的分类">2. Classifications of Resistance (耐药性的分类)</h4>
<h5 id="1-Intrinsic-Natural-Resistance-固有-天然耐药">1. Intrinsic / Natural Resistance (固有/天然耐药)</h5>
<p>The organism is naturally resistant without needing genetic mutation.</p>
<ul>
<li><strong>Examples:</strong>
<ul>
<li>Lactobacilli in yoghurt are intrinsically resistant to Vancomycin (not clinically problematic).</li>
<li>Gram-negative bacteria are intrinsically resistant to antibiotics that cannot cross their outer membrane.</li>
</ul>
</li>
<li><strong>Mechanisms:</strong>
<ul>
<li>Lack of target structure (没有靶点结构).</li>
<li>Impermeable to the antibiotic (对药物不通透).</li>
</ul>
</li>
</ul>
<h5 id="2-Acquired-Resistance-获得性耐药">2. Acquired Resistance (获得性耐药)</h5>
<p>A previously sensitive organism becomes resistant.</p>
<ul>
<li><strong>Driver:</strong> <strong>Darwinian Evolution / Natural Selection (自然选择)</strong>.
<ul>
<li>In a large population of bacteria (e.g., $10^8$ cells), a rare mutation may occur.</li>
<li>Applying an antibiotic kills the susceptible population (Susceptible cells).</li>
<li>The resistant mutant survives and proliferates (Selection pressure).</li>
</ul>
</li>
</ul>
<h4 id="3-Mechanisms-of-Resistance-耐药机制-How-the-drug-fails">3. Mechanisms of Resistance (耐药机制) - <em>How the drug fails</em></h4>
<p>There are four main molecular mechanisms by which bacteria resist drugs:</p>
<h5 id="A-Enzymatic-Inactivation-酶活灭活">A. Enzymatic Inactivation (酶活灭活)</h5>
<p>The bacteria produce enzymes that destroy or modify the drug.</p>
<ul>
<li><strong>Example:</strong> <strong>Beta-lactamases (</strong>$\beta$<strong>-内酰胺酶)</strong> hydrolyse the beta-lactam ring of penicillins and cephalosporins.</li>
<li><strong>Counter-strategy:</strong> Use Beta-lactamase inhibitors (e.g., Clavulanic acid).</li>
</ul>
<h5 id="B-Modification-of-the-Target-靶点修饰">B. Modification of the Target (靶点修饰)</h5>
<p>The bacteria alter the binding site so the drug can no longer attach.</p>
<ul>
<li><strong>Example:</strong> Altered PBP (Penicillin Binding Protein) in <strong>MRSA</strong> (Methicillin-Resistant <em>S. aureus</em>).</li>
<li><strong>Example:</strong> Methylation of the ribosome prevents macrolide binding.</li>
</ul>
<h5 id="C-Reduced-Permeability-Downregulation-of-Porins-降低通透性">C. Reduced Permeability / Downregulation of Porins (降低通透性)</h5>
<p>The bacteria stop the drug from entering the cell.</p>
<ul>
<li>Common in <strong>Gram-negative bacteria</strong> (e.g., <em>Pseudomonas aeruginosa</em>).</li>
<li>They close or downregulate <strong>Porin channels (孔蛋白通道)</strong> in the outer membrane.</li>
</ul>
<h5 id="D-Efflux-Pumps-外排泵">D. Efflux Pumps (外排泵)</h5>
<p>The bacteria actively pump the drug out of the cell before it can reach a toxic concentration.</p>
<ul>
<li>These are transmembrane proteins that eject antibiotics.</li>
</ul>
<h5 id="E-Biofilms-生物膜-A-Physiological-Mechanism">E. Biofilms (生物膜) - <em>A Physiological Mechanism</em></h5>
<ul>
<li><strong>Definition:</strong> An aggregate of microorganisms in which cells adhere to each other and/or to a surface.</li>
<li><strong>Examples:</strong> Dental plaque (牙菌斑), infections on catheters, heart valves, hip replacements.</li>
<li><strong>Resistance:</strong> Biofilms are <strong>phenotypically resistant (表型耐药)</strong>, not necessarily genetically resistant.
<ul>
<li>They require up to <strong>1000x higher concentration</strong> of antimicrobial to kill compared to planktonic (floating) bacteria.</li>
<li><em>Mechanism:</em> Slow growth rate, physical barrier matrix, altered microenvironment.</li>
</ul>
</li>
</ul>
<h4 id="4-Transmission-of-Resistance-耐药性的传播-How-genes-move">4. Transmission of Resistance (耐药性的传播) - <em>How genes move</em></h4>
<p>Bacteria can acquire resistance genes via <strong>Horizontal Gene Transfer (HGT/水平基因转移)</strong>.</p>
<ol>
<li><strong>Transformation (转化):</strong>
<ul>
<li>Uptake of “naked” extracellular DNA from the environment (often from dead bacteria) into the cell.</li>
</ul>
</li>
<li><strong>Conjugation (接合):</strong>
<ul>
<li>“Bacterial Mating”. Transfer of DNA (usually <strong>Plasmids</strong>) via direct cell-to-cell contact using a <strong>Pilus (菌毛)</strong>.</li>
<li>This is a major route for the spread of multi-drug resistance plasmids in hospitals.</li>
</ul>
</li>
<li><strong>Transduction (转导):</strong>
<ul>
<li>Transfer of DNA via <strong>Bacteriophages (噬菌体)</strong> (viruses that infect bacteria). The virus accidentally packages bacterial DNA and injects it into a new host.</li>
</ul>
</li>
</ol>
<h4 id="5-Drivers-of-Resistance-耐药性的驱动因素">5. Drivers of Resistance (耐药性的驱动因素)</h4>
<ul>
<li><strong>Overuse and Misuse (过度使用和滥用):</strong> Prescribing antibiotics for viral infections (colds, flu).</li>
<li><strong>Agricultural Use (农业用途):</strong>
<ul>
<li>Using antibiotics as growth promoters (Prophylactic use in livestock).</li>
<li><em>Risk:</em> Resistant bacteria from animals enter the human food chain (Trophallaxis concept).</li>
</ul>
</li>
<li><strong>Inadequate Infection Control:</strong> Poor hygiene in hospitals allows resistant clones to spread.</li>
<li><strong>Global Travel:</strong> Resistance mechanisms (e.g., NDM-1) spread rapidly across continents.</li>
<li><strong>Lack of New Drugs:</strong> The “Discovery Void”. Developing new antibiotics is expensive (~£1 billion) and difficult, leading to a lack of new drug classes since the 1980s.</li>
</ul>
<h5 id="The-“One-Health”-Concept-全健康-同一健康理念">The “One Health” Concept (全健康/同一健康理念)</h5>
<p>Recognizing that human health, animal health, and the environment are interconnected. Antibiotics released into the environment (sewage, manure) affect resistance in humans.</p>
<h4 id="6-Clinical-Consequences-Specific-Pathogens">6. Clinical Consequences &amp; Specific Pathogens</h4>
<h5 id="Key-Resistant-Organisms">Key Resistant Organisms</h5>
<ul>
<li><strong>MRSA:</strong> Methicillin-Resistant <em>Staphylococcus aureus</em>.</li>
<li><strong>VRE:</strong> Vancomycin-Resistant <em>Enterococci</em>.</li>
<li><strong>ESBL:</strong> Extended-Spectrum Beta-Lactamase producing bacteria (break down cephalosporins).</li>
<li><strong>CRE:</strong> Carbapenem-Resistant <em>Enterobacteriaceae</em> (Resistance to “last-resort” drugs).</li>
</ul>
<h5 id="Consequences">Consequences</h5>
<ul>
<li>Treatment failure.</li>
<li>Increased mortality and morbidity.</li>
<li>Prolonged hospital stays.</li>
<li>Increased healthcare costs.</li>
</ul>
<h4 id="7-Antimicrobial-Stewardship-抗微生物药物管理-导向">7. Antimicrobial Stewardship (抗微生物药物管理/导向)</h4>
<p><strong>Definition:</strong> An organisational or healthcare-system-wide approach to promoting and monitoring judicious use of antimicrobials to preserve their future effectiveness.</p>
<h5 id="Key-Strategies-AMS-Strategies">Key Strategies (AMS Strategies)</h5>
<ol>
<li><strong>Diagnosis &amp; Guidelines:</strong>
<ul>
<li>Only prescribe when there is clinical evidence of <strong>bacterial</strong> infection.</li>
<li>Follow local formulary/guidelines (First-line vs Second-line drugs).</li>
</ul>
</li>
<li><strong>Start Smart, Then Focus (精明开始，然后聚焦):</strong>
<ul>
<li><strong>Start Smart:</strong> If a patient is critically ill (e.g., Sepsis), start broad-spectrum antibiotics immediately (within 1 hour) after taking cultures.</li>
<li><strong>Then Focus (The 48-Hour Review):</strong> Review the prescription at <strong>48-72 hours</strong>.
<ul>
<li><strong>Options:</strong>
<ol>
<li><strong>Stop:</strong> If no infection is found.</li>
<li><strong>Switch:</strong> IV to Oral (if patient improves).</li>
<li><strong>Change:</strong> To a narrower spectrum agent based on culture results (De-escalation).</li>
<li><strong>Continue:</strong> If indicated.</li>
<li><strong>OPAT:</strong> Outpatient Parenteral Antibiotic Therapy.</li>
</ol>
</li>
</ul>
</li>
</ul>
</li>
<li><strong>Surgical Prophylaxis (外科预防):</strong>
<ul>
<li>Single dose given <strong>&lt;60 minutes before incision</strong>.</li>
<li>Do not continue for days after surgery (unless infection is present).</li>
</ul>
</li>
<li><strong>Combination Therapy:</strong>
<ul>
<li>Using multiple drugs to reduce the statistical probability of resistance developing (e.g., in <strong>Tuberculosis</strong> treatment).</li>
</ul>
</li>
</ol>
<h5 id="Summary-for-Pharmacists">Summary for Pharmacists</h5>
<ul>
<li>Understand the <strong>mechanism of action</strong> vs <strong>mechanism of resistance</strong>.</li>
<li>Promote <strong>compliance</strong> (completing courses).</li>
<li>Challenge unnecessary prescriptions.</li>
<li>Understand <strong>One Health</strong> and the global nature of the problem.</li>
</ul>
<h2 id="EBLs">EBLs</h2>
<h3 id="EBL-1-Recap-of-key-concepts">EBL 1 Recap of key concepts</h3>
<blockquote>
<ul>
<li>Appreciate how drugs selectively interact with their biological targets <em>(EBL task 3&amp;4)</em></li>
<li>Understand the mechanism of action of antimicrobial agents and be able to give examples <em>(EBL task 5)</em></li>
<li>Understand what is meant by selective toxicity in terms of infection management <em>(EBL task 5)</em></li>
<li>Define a cell and describe the structure and function of the major organelles <em>(EBL task 5)</em></li>
<li>Describe the main routes of administration and dosage types of medicines <em>(EBL task 7)</em></li>
</ul>
</blockquote>
<p><strong>Q3.</strong> Describe in detail the stepwise process involved in folding a primary polypeptide sequence into fully functional three-dimensional globular protein structure. In your answer mention all the forces which confer structural stability, taking into account the role of aqueous environment and also give some examples of typical amino acids involved in each such case.</p>
<blockquote>
<ol>
<li>Primary Structure</li>
</ol>
<ul>
<li>Linear chain of amino acids joined by peptide bonds (covalent, strong, stable).</li>
<li>Sequence determines folding.</li>
</ul>
<ol start="2">
<li>Secondary Structure</li>
</ol>
<ul>
<li>Local folding into α-helices and β-sheets, stabilized by hydrogen bonds between backbone -C=O and -N-H groups.</li>
<li>Examples: Ala, Leu (helix formers); Val, Ile (β-sheet formers).</li>
</ul>
<ol start="3">
<li>Supersecondary Motifs</li>
</ol>
<ul>
<li>Small combinations (β-α-β loops, hairpins) form the framework.</li>
</ul>
<ol start="4">
<li>Tertiary Structure</li>
</ol>
<ul>
<li>Folding into a compact 3D globular protein driven by interactions between side chains in aqueous environment:</li>
<li>Hydrophobic interactions: nonpolar residues (Val, Leu, Ile, Phe) cluster inside, away from water.</li>
<li>Hydrogen bonds: polar residues (Ser, Thr, Asn, Gln, Tyr) stabilize folding.</li>
<li>Ionic bonds / salt bridges: acidic (Asp, Glu) with basic (Lys, Arg, His).</li>
<li>Disulfide bonds: covalent crosslinks between two Cys residues.</li>
<li>van der Waals forces: weak packing interactions among closely aligned atoms.</li>
</ul>
<ol start="5">
<li>Quaternary Structure (if multi-subunit)</li>
</ol>
<ul>
<li>Assembly of more than one polypeptide chain, stabilized by the same non-covalent forces and sometimes disulfide bonds.</li>
<li>Example: Haemoglobin (α and β subunits).</li>
</ul>
<p>Role of Aqueous Environment</p>
<ul>
<li>Hydrophobic effect is the major driving force: nonpolar residues bury inside, while polar/charged residues orient to the surface to interact with water.</li>
<li>This minimizes free energy and creates a stable soluble globular structure.</li>
</ul>
</blockquote>
<p><strong>Q3.</strong> When considering how medicines work it is important that you understand the different terminology used and what it means. You will frequently encounter these terms as you learn about different medicines this year. Applying your previous learning on pharmacology principles please complete the below table.</p>
<blockquote>
<table>
<thead>
<tr>
<th><strong>Type of Target Interaction</strong></th>
<th><strong>Briefly explain what this means (one-two sentences)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>At a receptor</strong></td>
<td></td>
</tr>
<tr>
<td>Agonist</td>
<td>A drug (or endogenous ligand) that binds to a receptor and activates it, producing a biological response. Agonists mimic the action of natural signalling molecules (e.g., neurotransmitters, hormones).</td>
</tr>
<tr>
<td>Partial agonist</td>
<td>A drug that binds to a receptor and activates it, but produces a smaller (sub-maximal) response compared to a full agonist, even when all receptors are occupied.</td>
</tr>
<tr>
<td>Inverse agonist</td>
<td>A drug that binds to the same receptor site as an agonist but produces the opposite effect, reducing the receptor’s basal (constitutive) activity below its normal level.</td>
</tr>
<tr>
<td>Competitive antagonist</td>
<td>A drug that binds reversibly to the same receptor site as the agonist but does not activate it. It blocks the agonist from binding, and its effect can be overcome by increasing the concentration of the agonist.</td>
</tr>
<tr>
<td>Non-competitive antagonist</td>
<td>A drug that reduces or prevents the effect of an agonist by binding to a different site on the receptor (allosteric site) or by irreversibly binding to the active site. Its effect cannot be fully overcome by increasing agonist concentration, because it changes receptor function rather than just blocking access.</td>
</tr>
<tr>
<td>Negative allosteric modulator</td>
<td>A drug that binds to a receptor at a site different from the agonist (allosteric site) and decreases the receptor’s response to the agonist. It does not directly block the binding site but reduces the effect of the agonist by changing the shape of the active site.</td>
</tr>
<tr>
<td>Positive allosteric modulator</td>
<td>A drug that binds to a receptor at a site different from the agonist and enhances the receptor’s response to the agonist. It does not activate the receptor on its own but increases the effect of the agonist (e.g., by boosting potency or efficacy).</td>
</tr>
<tr>
<td><strong>At an enzyme</strong></td>
<td></td>
</tr>
<tr>
<td>Activator</td>
<td>A drug or molecule that binds to an enzyme and increases its activity, either by making the active site more effective or by promoting the enzyme’s normal function, leading to an increase in the rate of the reaction it catalyses.</td>
</tr>
<tr>
<td>Inducer</td>
<td>A drug that increases the amount or activity of an enzyme, often by stimulating its gene expression. This leads to faster metabolism of the enzyme’s substrates, which can reduce the effect of some medicines by lowering their concentration in the body.</td>
</tr>
<tr>
<td>Competitive inhibitor</td>
<td>A drug that binds reversibly to the active site of an enzyme, competing with the normal substrate. This prevents the substrate from binding and slows down the reaction, but the inhibition can be overcome by increasing the substrate concentration.</td>
</tr>
<tr>
<td>Non-competitive inhibitor</td>
<td>Binds to the enzyme at a different site (allosteric site) and decreases its catalytic activity. Its effect cannot be reversed by adding more substrate.</td>
</tr>
</tbody>
</table>
</blockquote>
<p><strong>Q5.</strong> HF is an 8-year-old boy who was taken to see his GP last week with fever and earache. On examination, HF showed signs of slight hearing loss and was irritable. He was prescribed a course of amoxicillin for an acute ear infection. His symptoms worsened and after three days his parents took him back to the GP, who has now prescribed a suspension of co-amoxiclav.</p>
<p>(a) Briefly discuss what a eukaryotic cell is and what a prokaryotic cell is. List <strong>FOUR</strong> physiological differences between eukaryotic and prokaryotic cells</p>
<blockquote>
<ul>
<li>Eukaryotic cell: a complex cell type that is subdivided into separate compartments by membranes.</li>
<li>Prokaryotic cell: a simpler cell type that is not subdivided by membranes.</li>
</ul>
<table>
<thead>
<tr>
<th></th>
<th><strong>Eukaryotic cell</strong></th>
<th><strong>Prokaryotic cell</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Organelles</td>
<td>contain membrane-bound organelles</td>
<td>lack membrane-bound organelles</td>
</tr>
<tr>
<td>Nucleus</td>
<td>membrane-bound nucleus</td>
<td>No nucleus;genomes within the nucleoid region</td>
</tr>
<tr>
<td>Ribosome</td>
<td>80S</td>
<td>70S</td>
</tr>
<tr>
<td>Cell wall</td>
<td>plants/fungi- cellulose or chitin walls; animal cells- no cell wall</td>
<td>mostly have peptidoglycan cell wall</td>
</tr>
</tbody>
</table>
</blockquote>
<p>(b) When considering antimicrobials, briefly explain what is meant by selective toxicity</p>
<blockquote>
<p>Ability of a drug to kill or inhibit a microbe while damaging the host as little as possible. Microbes have structures unique to them and the drug acts on those specific features making it more harmful to the microbe than the host. More of the drug accumulates in the microbe compared to the human cells.</p>
</blockquote>
<p>© Briefly describe what is meant be the terms bacteriostatic and bactericidal and give an example of an antibiotic within each category.</p>
<blockquote>
<table>
<thead>
<tr>
<th></th>
<th><strong>Bacteriostatic</strong></th>
<th><strong>Bactericidal</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Definition</td>
<td>An antibiotic that inhibits bacterial growth and reproduction but does not directly kill the bacteria.</td>
<td>An antibiotic that directly kills bacteria, leading to bacterial cell death.</td>
</tr>
<tr>
<td>Example</td>
<td>Tetracycline (Doxycycline), Macrolides (Erythromycin, Clarithromycin)</td>
<td>Penicillin, Cephalosporin, Aminoglycoside</td>
</tr>
</tbody>
</table>
</blockquote>
<p>(d) What is the rationale for prescribing co-amoxiclav to HF in the above scenario? Include in your answer an overview of the mode(s) of action for this drug.</p>
<blockquote>
<p>Co-amoxiclav is a combination of amoxicillin (a broad spectrum B lactam antibiotic) and clavulanic acid (B lactamase inhibitor).<br>
Amoxicillin inhibits cell wall synthesis by irreversibly binding to transpeptidase. Transpeptidase is needed by the microorganisms to produce cell walls (catalyses formation of cross links between polypeptide chains which provide rigidity). Amoxicillin contains a beta lactam ring which mimics the D-Ala-D-Ala terminus of peptide chain in peptidoglycan ( what the bacterial cell wall is made of) . The OH of transpeptidase binds to C7 of amoxicillin and  inactivated amoxicillin-enzyme-derivative forms. Cells burst as the cell wall can’t be cross linked properly so it weakens. Some bacteria produce B lactamase enzymes which deactivate amoxicillin by breaking the beta lactam ring. Clavulanic acid mimics the structure of a beta lactam ring, beta lactamase binds to it mistaking it for amoxicillin. Irreversibly inhibits beta lactamase allowing amoxicillin to work effectively<br>
Using co-amoxiclav is more effective in this case than amoxicillin alone as it protects amoxicillin from being deactivated.</p>
</blockquote>
<p><strong>Q6.</strong> One of the medicines you will have learnt about previously is omeprazole, a proton pump inhibitor (PPI). This medicine is one of the most commonly used medicines and has lots of different indications. <strong>Using only the BNF</strong>, answer the following:</p>
<p>a)  What is the recommended dose for prophylaxis in patients with a history of NSAID-associated gastric ulcer who require continued NSAID treatment</p>
<blockquote>
<p>The BNF indicates that for gastroprotection when an NSAID must be continued in someone with previous ulcer history, a standard PPI dose is used. For omeprazole, that is <strong>20 mg once daily</strong>.</p>
</blockquote>
<p>b)  What advice is given about administration of tablets containing enteric-coated pellets</p>
<blockquote>
<p>Tablets (Losec MUPS®, Mezzopram®) or capules (Losec®) containing enteric-coated pellets can be dispersed in non-carbonated water or a slightly acidic liquid e.g. fruit juice or apple sauce; do not use milk or carbonated water. The dispersion should be stirred just before drinking and taken immediately, rinsed down with half a glass of water. The enteric-coated pellets must not be chewed. Enteric-coated tablets (Dexcel®) must be swallowed whole and not chewed or crushed.</p>
</blockquote>
<p>c)  Briefly describe one moderate interaction and one severe interaction that Omeprazole has. For each interaction include the level of evidence and action message. What would you do in practice to manage each interaction?</p>
<blockquote>
<p><strong>Moderate interaction: Cilostazol</strong></p>
<p>Evidence: Study</p>
<p>Action message: Omeprazole is predicted to increase the exposure to Cilostazol. Manufacturer advises adjust Cilostazol dose.</p>
<p>Practice: In practice, the increased cilostazol exposure raises the risk of adverse effects (e.g. headache, palpitations, bleeding tendency). If a patient requires both omeprazole and cilostazol, check the cilostazol dose — manufacturers usually recommend reducing cilostazol from 100 mg twice daily to 50 mg twice daily when given with strong CYP2C19 inhibitors like omeprazole. Document the interaction, counsel the patient on signs of toxicity, and monitor response.</p>
<p><strong>Severe interaction: Citalopram</strong></p>
<p>Evidence: Study</p>
<p>Action message: Omeprazole moderately increases the exposure to Citalopram. Manufacturer advises monitor and adjust dose.</p>
<p>Practice: The concern is increased risk of QT prolongation and dose-dependent citalopram side effects (e.g. agitation, GI upset, arrhythmias). Consider whether an alternative antidepressant with lower interaction risk or an alternative PPI could be used. If co-prescribed, keep citalopram within the lower dose range. Monitor closely for side effects and ECG changes if risk factors are present (electrolyte imbalance, cardiac disease, higher age).</p>
</blockquote>
<h3 id="EBL-2-Immunity-1">EBL 2 Immunity 1</h3>
<blockquote>
<ul>
<li>Describe how pathogens cause disease and how they overcome the innate host defence</li>
<li>Describe the fundamentals of vaccination and named examples of successful vaccination campaigns</li>
<li>Demonstrate an understanding of, and describe the pathogenicity, epidemiology, management and prevention of urinary tract infection, *H pylori-*associated gastrointestinal disease, viral and bacterial skin and eye infections and viral and bacterial respiratory tract infections</li>
<li>Demonstrate an understanding of hypersensitivity reactions and the concept of allergy</li>
<li>Demonstrate an understanding of different formulations for parenteral application with particular focus on the delivery route (IV, IM, SC, infustion) including nano-formulation</li>
<li>Demonstrate a broad understanding of different types of vaccines and why they are used</li>
<li>Describe methods for delivery of drugs to the nose and lung.</li>
</ul>
</blockquote>
<p><img src="C:%5CUsers%5Cthyzz%5CAppData%5CRoaming%5CTypora%5Ctypora-user-images%5Cimage-20251202165638461.png" alt="image-20251202165638461"></p>
<ol>
<li>Discuss the innate immune defences present in a host to prevent microbial infection of the airway.</li>
</ol>
<blockquote></blockquote>
<ol start="2">
<li>Describe how pathogenic bacteria have evolved to infect the airway focusing on the concepts of host attachment, nutrient acquisition and immune evasion.</li>
</ol>
<blockquote></blockquote>
<ol start="3">
<li>It transpires that RB has community acquired bacterial pneumonia. Describe the key differences between hospital and community acquired bacterial pneumonia, in terms of microbiology</li>
</ol>
<blockquote></blockquote>
<ol start="4">
<li>With reference to the relevant NICE guidance, how would you assess the severity of the infection, referring to CURB65?</li>
</ol>
<blockquote></blockquote>
<ol start="5">
<li>How would you treat the infection? Give the chemical structure of your therapeutic compound and use this to discuss its mechanism of action and oral availability.</li>
</ol>
<blockquote></blockquote>
<ol start="6">
<li>What three vaccinations would you prioritise for RB and justify your answer.</li>
</ol>
<blockquote></blockquote>
<ol start="7">
<li>Discuss what type of vaccine technology would be required for your three vaccinations identified in question 5, with reference to the active ingredient and the formulation.</li>
</ol>
<blockquote></blockquote>
<ol start="8">
<li>Some of you will be on community pharmacy placements next week and may see vaccinations being provided in the pharmacy. For one of your recommended vaccines, what are the key side effects? What advice would you give to the patient?</li>
</ol>
<blockquote></blockquote>

                
            </div>
            <hr/>

            

    <div class="reprint" id="reprint-statement">
        
            <div class="reprint__author">
                <span class="reprint-meta" style="font-weight: bold;">
                    <i class="fas fa-user">
                        Author:
                    </i>
                </span>
                <span class="reprint-info">
                    <a href="https://thyzzs.top" rel="external nofollow noreferrer">thyzzs</a>
                </span>
            </div>
            <div class="reprint__type">
                <span class="reprint-meta" style="font-weight: bold;">
                    <i class="fas fa-link">
                        Link:
                    </i>
                </span>
                <span class="reprint-info">
                    <a href="https://thyzzs.top/2025/11/29/immunity-infection-and-respiratory-system/">https://thyzzs.top/2025/11/29/immunity-infection-and-respiratory-system/</a>
                </span>
            </div>
            <div class="reprint__notice">
                <span class="reprint-meta" style="font-weight: bold;">
                    <i class="fas fa-copyright">
                        Reprint policy:
                    </i>
                </span>
                <span class="reprint-info">
                    All articles in this blog are used except for special statements
                    <a href="https://creativecommons.org/licenses/by-nc-sa/4.0/deed.zh" rel="external nofollow noreferrer" target="_blank">CC BY-NC-SA 4.0</a>
                    reprint policy. If reproduced, please indicate source
                    <a href="https://thyzzs.top" target="_blank">thyzzs</a>
                    !
                </span>
            </div>
        
    </div>

    <script async defer>
      document.addEventListener("copy", function (e) {
        let toastHTML = '<span>Copied successfully, please follow the reprint policy of this article</span><button class="btn-flat toast-action" onclick="navToReprintStatement()" style="font-size: smaller">more</a>';
        M.toast({html: toastHTML})
      });

      function navToReprintStatement() {
        $("html, body").animate({scrollTop: $("#reprint-statement").offset().top - 80}, 800);
      }
    </script>



            <div class="tag_share" style="display: block;">
                <div class="post-meta__tag-list" style="display: inline-block;">
                    
                        <div class="article-tag">
                            
                                <a href="/tags/Biology/">
                                    <span class="chip bg-color">Biology</span>
                                </a>
                            
                        </div>
                    
                </div>
                <div class="post_share" style="zoom: 80%; width: fit-content; display: inline-block; float: right; margin: -0.15rem 0;">
                    <link rel="stylesheet" type="text/css" href="/libs/share/css/share.min.css">
<div id="article-share">

    
    <div class="social-share" data-sites="twitter,facebook,google,qq,qzone,wechat,weibo,douban,linkedin" data-wechat-qrcode-helper="<p>微信扫一扫即可分享！</p>"></div>
    <script src="/libs/share/js/social-share.min.js"></script>
    

    

</div>

                </div>
            </div>
            
        </div>
    </div>

    

    

    

    

    
        <style>
    .valine-card {
        margin: 1.5rem auto;
    }

    .valine-card .card-content {
        padding: 20px 20px 5px 20px;
    }

    #vcomments textarea {
        box-sizing: border-box;
        background: url("/medias/comment_bg.png") 100% 100% no-repeat;
    }

    #vcomments p {
        margin: 2px 2px 10px;
        font-size: 1.05rem;
        line-height: 1.78rem;
    }

    #vcomments blockquote p {
        text-indent: 0.2rem;
    }

    #vcomments a {
        padding: 0 2px;
        color: #4cbf30;
        font-weight: 500;
        text-decoration: none;
    }

    #vcomments img {
        max-width: 100%;
        height: auto;
        cursor: pointer;
    }

    #vcomments ol li {
        list-style-type: decimal;
    }

    #vcomments ol,
    ul {
        display: block;
        padding-left: 2em;
        word-spacing: 0.05rem;
    }

    #vcomments ul li,
    ol li {
        display: list-item;
        line-height: 1.8rem;
        font-size: 1rem;
    }

    #vcomments ul li {
        list-style-type: disc;
    }

    #vcomments ul ul li {
        list-style-type: circle;
    }

    #vcomments table, th, td {
        padding: 12px 13px;
        border: 1px solid #dfe2e5;
    }

    #vcomments table, th, td {
        border: 0;
    }

    table tr:nth-child(2n), thead {
        background-color: #fafafa;
    }

    #vcomments table th {
        background-color: #f2f2f2;
        min-width: 80px;
    }

    #vcomments table td {
        min-width: 80px;
    }

    #vcomments h1 {
        font-size: 1.85rem;
        font-weight: bold;
        line-height: 2.2rem;
    }

    #vcomments h2 {
        font-size: 1.65rem;
        font-weight: bold;
        line-height: 1.9rem;
    }

    #vcomments h3 {
        font-size: 1.45rem;
        font-weight: bold;
        line-height: 1.7rem;
    }

    #vcomments h4 {
        font-size: 1.25rem;
        font-weight: bold;
        line-height: 1.5rem;
    }

    #vcomments h5 {
        font-size: 1.1rem;
        font-weight: bold;
        line-height: 1.4rem;
    }

    #vcomments h6 {
        font-size: 1rem;
        line-height: 1.3rem;
    }

    #vcomments p {
        font-size: 1rem;
        line-height: 1.5rem;
    }

    #vcomments hr {
        margin: 12px 0;
        border: 0;
        border-top: 1px solid #ccc;
    }

    #vcomments blockquote {
        margin: 15px 0;
        border-left: 5px solid #42b983;
        padding: 1rem 0.8rem 0.3rem 0.8rem;
        color: #666;
        background-color: rgba(66, 185, 131, .1);
    }

    #vcomments pre {
        font-family: monospace, monospace;
        padding: 1.2em;
        margin: .5em 0;
        background: #272822;
        overflow: auto;
        border-radius: 0.3em;
        tab-size: 4;
    }

    #vcomments code {
        font-family: monospace, monospace;
        padding: 1px 3px;
        font-size: 0.92rem;
        color: #e96900;
        background-color: #f8f8f8;
        border-radius: 2px;
    }

    #vcomments pre code {
        font-family: monospace, monospace;
        padding: 0;
        color: #e8eaf6;
        background-color: #272822;
    }

    #vcomments pre[class*="language-"] {
        padding: 1.2em;
        margin: .5em 0;
    }

    #vcomments code[class*="language-"],
    pre[class*="language-"] {
        color: #e8eaf6;
    }

    #vcomments [type="checkbox"]:not(:checked), [type="checkbox"]:checked {
        position: inherit;
        margin-left: -1.3rem;
        margin-right: 0.4rem;
        margin-top: -1px;
        vertical-align: middle;
        left: unset;
        visibility: visible;
    }

    #vcomments b,
    strong {
        font-weight: bold;
    }

    #vcomments dfn {
        font-style: italic;
    }

    #vcomments small {
        font-size: 85%;
    }

    #vcomments cite {
        font-style: normal;
    }

    #vcomments mark {
        background-color: #fcf8e3;
        padding: .2em;
    }

    #vcomments table, th, td {
        padding: 12px 13px;
        border: 1px solid #dfe2e5;
    }

    table tr:nth-child(2n), thead {
        background-color: #fafafa;
    }

    #vcomments table th {
        background-color: #f2f2f2;
        min-width: 80px;
    }

    #vcomments table td {
        min-width: 80px;
    }

    #vcomments [type="checkbox"]:not(:checked), [type="checkbox"]:checked {
        position: inherit;
        margin-left: -1.3rem;
        margin-right: 0.4rem;
        margin-top: -1px;
        vertical-align: middle;
        left: unset;
        visibility: visible;
    }
</style>

<div class="card valine-card" data-aos="fade-up">
    <div class="comment_headling" style="font-size: 20px; font-weight: 700; position: relative; padding-left: 20px; top: 15px; padding-bottom: 5px;">
        <i class="fas fa-comments fa-fw" aria-hidden="true"></i>
        <span>评论</span>
    </div>
    <div id="vcomments" class="card-content" style="display: grid">
    </div>
</div>

<script src="/libs/valine/av-min.js"></script>
<script src="https://unpkg.com/valine/dist/Valine.min.js"></script>
<script>
    new Valine({
        el: '#vcomments',
        appId: '102OcU05Y8Tw9VQ0bl9I0Msv-gzGzoHsz',
        appKey: 's2tfPOVV1WnY0EMDuI9HKqEA',
        serverURLs: '',
        notify: 'false' === 'true',
        verify: 'false' === 'true',
        visitor: 'true' === 'true',
        avatar: 'mm',
        pageSize: '10',
        lang: 'en',
        placeholder: 'just go go'
    });
</script>

<!--酷Q推送-->


    

    

    

    

    

<article id="prenext-posts" class="prev-next articles">
    <div class="row article-row">
        
        <div class="article col s12 m6" data-aos="fade-up" data-aos="fade-up">
            <div class="article-badge left-badge text-color">
                <i class="far fa-dot-circle"></i>&nbsp;Current
            </div>
            <div class="card">
                <a href="/2025/11/29/immunity-infection-and-respiratory-system/">
                    <div class="card-image">
                        
                        
                        <img src="/medias/featureimages/13.jpg" class="responsive-img" alt="Immunity, Infection and Respiratory System">
                        
                        <span class="card-title">Immunity, Infection and Respiratory System</span>
                    </div>
                </a>
                <div class="card-content article-content">
                    <div class="summary block-with-text">
                        
                            
                        
                    </div>
                    <div class="publish-info">
                            <span class="publish-date">
                                <i class="far fa-clock fa-fw icon-date"></i>2025-11-29
                            </span>
                        <span class="publish-author">
                            
                            <i class="fas fa-bookmark fa-fw icon-category"></i>
                            
                            <a href="/categories/Course-Notes/" class="post-category">
                                    Course Notes
                                </a>
                            
                            
                        </span>
                    </div>
                </div>

                
                <div class="card-action article-tags">
                    
                    <a href="/tags/Biology/">
                        <span class="chip bg-color">Biology</span>
                    </a>
                    
                </div>
                
            </div>
        </div>
        
        
        <div class="article col s12 m6" data-aos="fade-up">
            <div class="article-badge right-badge text-color">
                Next&nbsp;<i class="fas fa-chevron-right"></i>
            </div>
            <div class="card">
                <a href="/2025/08/12/future/">
                    <div class="card-image">
                        
                        
                        <img src="/medias/featureimages/6.jpg" class="responsive-img" alt="关于未来">
                        
                        <span class="card-title">关于未来</span>
                    </div>
                </a>
                <div class="card-content article-content">
                    <div class="summary block-with-text">
                        
                            然后，向着明天——
                        
                    </div>
                    <div class="publish-info">
                            <span class="publish-date">
                                <i class="far fa-clock fa-fw icon-date"></i>2025-08-13
                            </span>
                        <span class="publish-author">
                            
                            <i class="fas fa-bookmark fa-fw icon-category"></i>
                            
                            <a href="/categories/Stack/" class="post-category">
                                    Stack
                                </a>
                            
                            
                        </span>
                    </div>
                </div>
                
                <div class="card-action article-tags">
                    
                    <a href="/tags/Stack/">
                        <span class="chip bg-color">Stack</span>
                    </a>
                    
                </div>
                
            </div>
        </div>
        
    </div>
</article>

</div>


<script>
    $('#articleContent').on('copy', function (e) {
        // IE8 or earlier browser is 'undefined'
        if (typeof window.getSelection === 'undefined') return;

        var selection = window.getSelection();
        // if the selection is short let's not annoy our users.
        if (('' + selection).length < Number.parseInt('120')) {
            return;
        }

        // create a div outside of the visible area and fill it with the selected text.
        var bodyElement = document.getElementsByTagName('body')[0];
        var newdiv = document.createElement('div');
        newdiv.style.position = 'absolute';
        newdiv.style.left = '-99999px';
        bodyElement.appendChild(newdiv);
        newdiv.appendChild(selection.getRangeAt(0).cloneContents());

        // we need a <pre> tag workaround.
        // otherwise the text inside "pre" loses all the line breaks!
        if (selection.getRangeAt(0).commonAncestorContainer.nodeName === 'PRE' || selection.getRangeAt(0).commonAncestorContainer.nodeName === 'CODE') {
            newdiv.innerHTML = "<pre>" + newdiv.innerHTML + "</pre>";
        }

        var url = document.location.href;
        newdiv.innerHTML += '<br />'
            + 'From: 天何言哉<br />'
            + 'Author: thyzzs<br />'
            + 'Link: <a href="' + url + '">' + url + '</a><br />'
            + '本文章著作权归作者所有，任何形式的转载都请注明出处。';

        selection.selectAllChildren(newdiv);
        window.setTimeout(function () {bodyElement.removeChild(newdiv);}, 200);
    });
</script>


<!-- 代码块功能依赖 -->
<script type="text/javascript" src="/libs/codeBlock/codeBlockFuction.js"></script>


  <!-- 是否加载使用自带的 prismjs. -->
  <script type="text/javascript" src="/libs/prism/prism.min.js"></script>


<!-- 代码语言 -->

<script type="text/javascript" src="/libs/codeBlock/codeLang.js"></script>


<!-- 代码块复制 -->

<script type="text/javascript" src="/libs/codeBlock/codeCopy.js"></script>


<!-- 代码块收缩 -->

<script type="text/javascript" src="/libs/codeBlock/codeShrink.js"></script>



    </div>
    <div id="toc-aside" class="expanded col l3 hide-on-med-and-down">
        <div class="toc-widget card" style="background-color: white;">
            <div class="toc-title"><i class="far fa-list-alt"></i>&nbsp;&nbsp;TOC</div>
            <div id="toc-content"></div>
        </div>
    </div>
</div>

<!-- TOC 悬浮按钮. -->

<div id="floating-toc-btn" class="hide-on-med-and-down">
    <a class="btn-floating btn-large bg-color">
        <i class="fas fa-list-ul"></i>
    </a>
</div>


<script src="/libs/tocbot/tocbot.min.js"></script>
<script>
    $(function () {
        tocbot.init({
            tocSelector: '#toc-content',
            contentSelector: '#articleContent',
            headingsOffset: -($(window).height() * 0.4 - 45),
            collapseDepth: Number('0'),
            headingSelector: 'h2, h3, h4'
        });

        // Set scroll toc fixed.
        let tocHeight = parseInt($(window).height() * 0.4 - 64);
        let $tocWidget = $('.toc-widget');
        $(window).scroll(function () {
            let scroll = $(window).scrollTop();
            /* add post toc fixed. */
            if (scroll > tocHeight) {
                $tocWidget.addClass('toc-fixed');
            } else {
                $tocWidget.removeClass('toc-fixed');
            }
        });

        
        /* 修复文章卡片 div 的宽度. */
        let fixPostCardWidth = function (srcId, targetId) {
            let srcDiv = $('#' + srcId);
            if (srcDiv.length === 0) {
                return;
            }

            let w = srcDiv.width();
            if (w >= 450) {
                w = w + 21;
            } else if (w >= 350 && w < 450) {
                w = w + 18;
            } else if (w >= 300 && w < 350) {
                w = w + 16;
            } else {
                w = w + 14;
            }
            $('#' + targetId).width(w);
        };

        // 切换TOC目录展开收缩的相关操作.
        const expandedClass = 'expanded';
        let $tocAside = $('#toc-aside');
        let $mainContent = $('#main-content');
        $('#floating-toc-btn .btn-floating').click(function () {
            if ($tocAside.hasClass(expandedClass)) {
                $tocAside.removeClass(expandedClass).hide();
                $mainContent.removeClass('l9');
            } else {
                $tocAside.addClass(expandedClass).show();
                $mainContent.addClass('l9');
            }
            fixPostCardWidth('artDetail', 'prenext-posts');
        });
        
    });
</script>

    

</main>


<script src="https://cdn.bootcss.com/mathjax/2.7.5/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
<script>
    MathJax.Hub.Config({
        tex2jax: {inlineMath: [['$', '$'], ['\\(', '\\)']]}
    });
</script>



    <footer class="page-footer bg-color">
    
        <link rel="stylesheet" href="/libs/aplayer/APlayer.min.css">
<style>
    .aplayer .aplayer-lrc p {
        
        display: none;
        
        font-size: 12px;
        font-weight: 700;
        line-height: 16px !important;
    }

    .aplayer .aplayer-lrc p.aplayer-lrc-current {
        
        display: none;
        
        font-size: 15px;
        color: #42b983;
    }

    
    .aplayer.aplayer-fixed.aplayer-narrow .aplayer-body {
        left: -66px !important;
    }

    .aplayer.aplayer-fixed.aplayer-narrow .aplayer-body:hover {
        left: 0px !important;
    }

    
</style>
<div class="">
    
    <div class="row">
        <meting-js class="col l8 offset-l2 m10 offset-m1 s12"
                   server="netease"
                   type="playlist"
                   id="911214248"
                   fixed='true'
                   autoplay='false'
                   theme='#42b983'
                   loop='all'
                   order='random'
                   preload='auto'
                   volume='0.7'
                   list-folded='true'
        >
        </meting-js>
    </div>
</div>

<script src="/libs/aplayer/APlayer.min.js"></script>
<script src="/libs/aplayer/Meting.min.js"></script>

    

    <div class="container row center-align"
         style="margin-bottom: 15px !important;">
        <div class="col s12 m8 l8 copy-right">
            Copyright&nbsp;&copy;
            
                <span id="year">2019-2025</span>
            
            <a href="/about" target="_blank">thyzzs</a>
            |&nbsp;Powered by&nbsp;<a href="https://hexo.io/" target="_blank">Hexo</a>
            |&nbsp;Theme&nbsp;<a href="https://github.com/blinkfox/hexo-theme-matery" target="_blank">Matery</a>
            
                <span id="translate">|&nbsp;繁/简：</span><a id="translateLink" href="javascript:translatePage();">繁</a>
            
            <br>
            
                &nbsp;<i class="fas fa-chart-area"></i>&nbsp;Total Words:&nbsp;<span
                        class="white-color">209.6k</span>
            
            
            
                
            
            
                <span id="busuanzi_container_site_pv">
                &nbsp;|&nbsp;<i class="far fa-eye"></i>&nbsp;Total visits:&nbsp;
                    <span id="busuanzi_value_site_pv" class="white-color"></span>
            </span>
            
            
                <span id="busuanzi_container_site_uv">
                &nbsp;|&nbsp;<i class="fas fa-users"></i>&nbsp;Total visitors:&nbsp;
                    <span id="busuanzi_value_site_uv" class="white-color"></span>
            </span>
            
            <br>

            <!-- 运行天数提醒. -->
            
                <span id="sitetime"> Loading ...</span>
                <script>
                    var calcSiteTime = function () {
                        var seconds = 1000;
                        var minutes = seconds * 60;
                        var hours = minutes * 60;
                        var days = hours * 24;
                        var years = days * 365;
                        var today = new Date();
                        var startYear = "2019";
                        var startMonth = "6";
                        var startDate = "28";
                        var startHour = "0";
                        var startMinute = "0";
                        var startSecond = "0";
                        var todayYear = today.getFullYear();
                        var todayMonth = today.getMonth() + 1;
                        var todayDate = today.getDate();
                        var todayHour = today.getHours();
                        var todayMinute = today.getMinutes();
                        var todaySecond = today.getSeconds();
                        var t1 = Date.UTC(startYear, startMonth, startDate, startHour, startMinute, startSecond);
                        var t2 = Date.UTC(todayYear, todayMonth, todayDate, todayHour, todayMinute, todaySecond);
                        var diff = t2 - t1;
                        var diffYears = Math.floor(diff / years);
                        var diffDays = Math.floor((diff / days) - diffYears * 365);

                        // 区分是否有年份.
                        var language = 'en-uk';
                        if (startYear === String(todayYear)) {
                            document.getElementById("year").innerHTML = todayYear;
                            var daysTip = 'This site has been running for ' + diffDays + ' days';
                            if (language === 'zh-CN') {
                                daysTip = '本站已运行 ' + diffDays + ' 天';
                            } else if (language === 'zh-HK') {
                                daysTip = '本站已運行 ' + diffDays + ' 天';
                            }
                            document.getElementById("sitetime").innerHTML = daysTip;
                        } else {
                            document.getElementById("year").innerHTML = startYear + " - " + todayYear;
                            var yearsAndDaysTip = 'This site has been running for ' + diffYears + ' years and '
                                + diffDays + ' days';
                            if (language === 'zh-CN') {
                                yearsAndDaysTip = '本站已运行 ' + diffYears + ' 年 ' + diffDays + ' 天';
                            } else if (language === 'zh-HK') {
                                yearsAndDaysTip = '本站已運行 ' + diffYears + ' 年 ' + diffDays + ' 天';
                            }
                            document.getElementById("sitetime").innerHTML = yearsAndDaysTip;
                        }
                    }

                    calcSiteTime();
                </script>
            
            <br>
            
        </div>
        <div class="col s12 m4 l4 social-link social-statis">
    <a href="https://github.com/thyzzs" class="tooltipped" target="_blank" data-tooltip="访问我的GitHub" data-position="top" data-delay="50">
        <i class="fab fa-github"></i>
    </a>



    <a href="mailto:thyzzs@163.com" class="tooltipped" target="_blank" data-tooltip="邮件联系我" data-position="top" data-delay="50">
        <i class="fas fa-envelope-open"></i>
    </a>





    <a href="https://twitter.com/thyzzs" class="tooltipped" target="_blank" data-tooltip="关注我的Twitter: https://twitter.com/thyzzs" data-position="top" data-delay="50">
        <i class="fab fa-twitter"></i>
    </a>



    <a href="tencent://AddContact/?fromId=50&fromSubId=1&subcmd=all&uin=1458077873" class="tooltipped" target="_blank" data-tooltip="QQ联系我: 1458077873" data-position="top" data-delay="50">
        <i class="fab fa-qq"></i>
    </a>





    <a href="https://www.zhihu.com/people/thyzzs" class="tooltipped" target="_blank" data-tooltip="关注我的知乎: https://www.zhihu.com/people/thyzzs" data-position="top" data-delay="50">
        <i class="fab fa-zhihu1">知</i>
    </a>



    <a href="/atom.xml" class="tooltipped" target="_blank" data-tooltip="RSS 订阅" data-position="top" data-delay="50">
        <i class="fas fa-rss"></i>
    </a>

</div>
    </div>
</footer>

<div class="progress-bar"></div>


    <!-- 搜索遮罩框 -->
<div id="searchModal" class="modal">
    <div class="modal-content">
        <div class="search-header">
            <span class="title"><i class="fas fa-search"></i>&nbsp;&nbsp;Search</span>
            <input type="search" id="searchInput" name="s" placeholder="Please enter a search keyword"
                   class="search-input">
        </div>
        <div id="searchResult"></div>
    </div>
</div>

<script type="text/javascript">
$(function () {
    var searchFunc = function (path, search_id, content_id) {
        'use strict';
        $.ajax({
            url: path,
            dataType: "xml",
            success: function (xmlResponse) {
                // get the contents from search data
                var datas = $("entry", xmlResponse).map(function () {
                    return {
                        title: $("title", this).text(),
                        content: $("content", this).text(),
                        url: $("url", this).text()
                    };
                }).get();
                var $input = document.getElementById(search_id);
                var $resultContent = document.getElementById(content_id);
                $input.addEventListener('input', function () {
                    var str = '<ul class=\"search-result-list\">';
                    var keywords = this.value.trim().toLowerCase().split(/[\s\-]+/);
                    $resultContent.innerHTML = "";
                    if (this.value.trim().length <= 0) {
                        return;
                    }
                    // perform local searching
                    datas.forEach(function (data) {
                        var isMatch = true;
                        var data_title = data.title.trim().toLowerCase();
                        var data_content = data.content.trim().replace(/<[^>]+>/g, "").toLowerCase();
                        var data_url = data.url;
                        data_url = data_url.indexOf('/') === 0 ? data.url : '/' + data_url;
                        var index_title = -1;
                        var index_content = -1;
                        var first_occur = -1;
                        // only match artiles with not empty titles and contents
                        if (data_title !== '' && data_content !== '') {
                            keywords.forEach(function (keyword, i) {
                                index_title = data_title.indexOf(keyword);
                                index_content = data_content.indexOf(keyword);
                                if (index_title < 0 && index_content < 0) {
                                    isMatch = false;
                                } else {
                                    if (index_content < 0) {
                                        index_content = 0;
                                    }
                                    if (i === 0) {
                                        first_occur = index_content;
                                    }
                                }
                            });
                        }
                        // show search results
                        if (isMatch) {
                            str += "<li><a href='" + data_url + "' class='search-result-title'>" + data_title + "</a>";
                            var content = data.content.trim().replace(/<[^>]+>/g, "");
                            if (first_occur >= 0) {
                                // cut out 100 characters
                                var start = first_occur - 20;
                                var end = first_occur + 80;
                                if (start < 0) {
                                    start = 0;
                                }
                                if (start === 0) {
                                    end = 100;
                                }
                                if (end > content.length) {
                                    end = content.length;
                                }
                                var match_content = content.substr(start, end);
                                // highlight all keywords
                                keywords.forEach(function (keyword) {
                                    var regS = new RegExp(keyword, "gi");
                                    match_content = match_content.replace(regS, "<em class=\"search-keyword\">" + keyword + "</em>");
                                });

                                str += "<p class=\"search-result\">" + match_content + "...</p>"
                            }
                            str += "</li>";
                        }
                    });
                    str += "</ul>";
                    $resultContent.innerHTML = str;
                });
            }
        });
    };

    searchFunc('/search.xml', 'searchInput', 'searchResult');
});
</script>

    <!-- 白天和黑夜主题 -->
<div class="stars-con">
    <div id="stars"></div>
    <div id="stars2"></div>
    <div id="stars3"></div>  
</div>

<script>
    function switchNightMode() {
        $('<div class="Cuteen_DarkSky"><div class="Cuteen_DarkPlanet"></div></div>').appendTo($('body')),
        setTimeout(function () {
            $('body').hasClass('DarkMode') 
            ? ($('body').removeClass('DarkMode'), localStorage.setItem('isDark', '0'), $('#sum-moon-icon').removeClass("fa-sun").addClass('fa-moon')) 
            : ($('body').addClass('DarkMode'), localStorage.setItem('isDark', '1'), $('#sum-moon-icon').addClass("fa-sun").removeClass('fa-moon')),
            
            setTimeout(function () {
            $('.Cuteen_DarkSky').fadeOut(1e3, function () {
                $(this).remove()
            })
            }, 2e3)
        })
    }
</script>

    <!-- 回到顶部按钮 -->
<div id="backTop" class="top-scroll">
    <a class="btn-floating btn-large waves-effect waves-light" href="#!">
        <i class="fas fa-arrow-up"></i>
    </a>
</div>


    <script src="/libs/materialize/materialize.min.js"></script>
    <script src="/libs/masonry/masonry.pkgd.min.js"></script>
    <script src="/libs/aos/aos.js"></script>
    <script src="/libs/scrollprogress/scrollProgress.min.js"></script>
    <script src="/libs/lightGallery/js/lightgallery-all.min.js"></script>
    <script src="/js/matery.js"></script>

    

    
        <script type="text/javascript" src="/js/tw_cn.js"></script>
        <script type="text/javascript">
          var defaultEncoding = 2; //网站编写字体是否繁体，1-繁体，2-简体
          var translateDelay = 0; //延迟时间,若不在前, 要设定延迟翻译时间, 如100表示100ms,默认为0
          var cookieDomain = "https://thyzzs.top"; //Cookie地址, 一定要设定, 通常为你的网址
          var msgToTraditionalChinese = "繁"; //此处可以更改为你想要显示的文字
          var msgToSimplifiedChinese = "简"; //同上，但两处均不建议更改
          var translateButtonId = "translateLink"; //默认互换id
          translateInitilization();
        </script>
    
    
    

    <!-- 雪花特效 -->
    

    <!-- 鼠标星星特效 -->
    

    

    <!-- Baidu Analytics -->

    <!-- Baidu Push -->

<script>
    (function () {
        var bp = document.createElement('script');
        var curProtocol = window.location.protocol.split(':')[0];
        if (curProtocol === 'https') {
            bp.src = 'https://zz.bdstatic.com/linksubmit/push.js';
        } else {
            bp.src = 'http://push.zhanzhang.baidu.com/push.js';
        }
        var s = document.getElementsByTagName("script")[0];
        s.parentNode.insertBefore(bp, s);
    })();
</script>

    
    <script src="/libs/others/clicklove.js" async="async"></script>
    
    
    <script async src="/libs/others/busuanzi.pure.mini.js"></script>
    

    

    

    <!--腾讯兔小巢-->
    
    
    <script type="text/javascript" color="0,0,255"
        pointColor="0,0,255" opacity='0.7'
        zIndex="-1" count="99"
        src="/libs/background/canvas-nest.js"></script>
    

    

    
    <script type="text/javascript" src="/libs/background/ribbon-dynamic.js" async="async"></script>
    

    
    <script src="/libs/instantpage/instantpage.js" type="module"></script>
    

</body>

</html>
